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 i 
Abstract 
 
Impaired functioning is recognized as a major barrier to recovery among individuals with 
psychotic disorders. Research on the role of negative symptomatology on functioning has 
identified avolition (i.e. lack of motivation) as being highly correlated with functional outcomes. 
However, current measures of avolition fail to consider more intrinsic factors that influence 
motivation. There is a need for more nuanced research on the drivers of motivation and their 
relationship with functioning to inform the observed relationship between avolition and impaired 
functioning. This cross-sectional study uses data obtained from the Prevention and Early 
Intervention Program for Psychoses, in London, Ontario. 105 clients of PEPP were assessed 
using validated measures of motivational drivers. Multivariate analyses did not show a 
statistically significant relationship between the intrinsic drivers of motivation and functional 
outcomes. Findings demonstrate the need for updated measures of negative symptoms as well as 
the need for further research on motivation and functional outcomes.   
 
Keywords 
psychotic disorders, schizophrenia, negative symptoms, motivation, avolition, functional 
outcomes  
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Chapter 1 
1 Introduction 
In this chapter, an overview of the thesis topic is provided in Section 1.1 followed by the 
research objectives in Section 1.2. Finally, Section 1.3 provides an overview of the structure of 
this thesis manuscript as well as the role of the student in the research process.  
 
1.1 Overview of Topic 
Defined as a loss of contact with reality, people suffering from psychosis often have difficulties 
distinguishing between what is real and what is not 1. These breaks from reality, often with a first 
onset during late adolescence and young adulthood 2, lead to disruptions in academic or 
professional, personal, and social lives. Psychotic episodes can occur in the context of both 
primary psychotic disorders as well as mood disorders with psychotic features. Primary 
psychotic disorders are ones in which psychotic symptomology are the primary symptoms, with 
disorders such as schizophrenia falling under this category 3-5. Mood disorders with psychotic 
features are instances where an individual will have a primary diagnosis of a mood disorder, such 
as depression, however they also exhibit psychotic symptoms3-5. Although no direct cause has 
been identified as leading to the development of psychosis, a number of possible risk factors 
have been identified such as substance use, cognitive deficits and other medical conditions6. 
Symptoms of psychotic disorders include delusions and hallucinations, thought disorders, social 
withdrawal, and lack of motivation - with the majority of symptoms falling into one of two 
categories, positive or negative symptoms 7-9. Positive symptoms consist of hallucinations, 
delusions and disturbances of thought, whereas negative symptoms consist of behaviors such as 
reduced emotional expressivity and social withdrawal, indicative of a reduction or loss of typical 
behaviors 10,11. Although psychotic disorders are considered chronic illnesses, within the last 
decade advances have been made in regard to treatment options, often consisting of antipsychotic 
medications in conjunction with psychosocial therapeutic interventions 12. Our current 
understanding of treating psychosis recognizes the importance of an early intervention approach 
12-17, with past research demonstrating the detrimental effects that a long duration of untreated 
psychosis can have on disorder progression and outcome 16. 
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Although symptomatic recovery is often achievable with treatment, functional recovery, defined 
as a sustained improvement in social and vocational functioning 15, remains more elusive, with 
impairments being found in both acute and chronic cases of psychotic disorders18,19. Growing 
interest in understanding why functional outcomes are more resistant to treatment has led to a 
surge in research attempting to pinpoint correlates of poor functioning. Negative symptoms, 
being one of the two key symptom categories defining psychotic symptomology, have 
consistently been shown to have a high correlation with functional outcomes 20-25. Recent 
evidence has shown that when controlling for other symptoms, such as positive symptoms, 
depression, and anxiety, negative symptoms remain a strong correlate of functioning26. Research 
has shown that one negative symptom in particular seems to outweigh the others in terms of its 
correlation to functional outcomes. Specifically, avolition, defined as a lack of motivation, has 
been identified as a strong correlate of functioning 22,23,25,27-30. 
 
Limitations in the methods used to measure negative symptoms may be inflating the contribution 
of negative symptoms. Measures of avolition that are currently used, such as the avolition 
subscale of the Scale for the Assessment of Negative Symptoms (SANS)31 or the Positive and 
Negative Syndrome Scale (PANSS)32, assesses overt behavioral markers rather than intrinsic 
motivational states. As such, it is highly possible that the strong, positive correlation observed 
between avolition and functioning may be due to the fact that these measures are assessing the 
same construct, specifically daily behavioral markers such as personal grooming habits and 
occupational/academic ability. Given this high degree of overlap between measures of avolition 
and functioning, there is a need for a more in-depth assessment of motivational deficits and their 
relationship to functional outcomes to better assess the possible relationship between avolition 
and impaired functioning.  
 
1.2 Purpose of Thesis and Research Objectives 
The overall goal of this thesis was to examine the relationship between the negative symptom of 
avolition and functional outcomes via intrinsic drivers of motivation in a cross-section of people 
with primary psychotic disorders. To assess the proposed relationship between motivation and 
functioning, we used data from 105 clients of an early psychosis intervention program to 
complete the following objectives: 
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• To examine the direct relationship between intrinsic drivers of motivation and overall level of 
functioning, adjusting for covariates; and 
• To examine the direct relationship between the intrinsic drivers of motivation and specific 
subdomains of functioning, specifically working ability, independent living and self-care, 
immediate social networks, and extended social networks, adjusting for possible covariates. 
 
1.3 Thesis Overview and Student Contribution 
In the following chapters, I will present a detailed review of the current literature on psychotic 
disorders, negative symptoms, and functional outcomes, along with a critical evaluation of 
related studies assessing motivation and functioning in people with psychotic disorders (Chapter 
2). Then I will present the methods used in this thesis, along with information regarding the data 
source, the multiple imputation method used to address missing data, and the variables and 
measures used to assess our exposures and outcome (Chapter 3). Subsequently, I will present and 
summarize the main findings of our analyses along with the results from our additional 
sensitivity analyses undertaken to assess the robustness of our main analyses (Chapter 4). 
Finally, I will provide a discussion of our key findings, the overall strengths and limitations of 
this thesis, and the implications of this study for future research and clinical care. 
The student’s contribution to the current study consisted of selection of the thesis topic, in 
collaboration with thesis supervisors, Dr. Arlene G. MacDougall and Dr. Kelly K. Anderson, and 
Dr. Ross M.G Norman, the principal investigator of the source study and a member of the thesis 
supervisory committee. Study objectives were formulated with insight from the thesis 
supervisory committee, and all subsequent phases of the study were developed and produced by 
the student, from development of the methodological plan to the preparation of this manuscript, 
in consultation with supervisors Dr. MacDougall and Dr. Anderson. 
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Chapter 2 
2 Literature Review 
This chapter will present an overview of psychotic disorders, negative symptoms, and functional 
outcomes in Sections 2.1, 2.2 and 2.3 respectively. Issues regarding the measurement of negative 
symptoms, individually and with respect to functional outcome assessments, are discussed in 
Section 2.4. The search strategy used to identify motivational drivers is reported in Section 2.5, 
along with the results from our literature search. Gaps in current knowledge are discussed in 
Section 2.6. Lastly, our study rationale and thesis objectives and hypotheses will be presented in 
Sections 2.7 and 2.8, respectively.  
 
2.1 Psychosis 
2.1.1 Overview 
Psychosis can be characterized as disturbances in thought, perception, and behavior 7. As defined 
by the Diagnostic and Statistical Manual on Mental Disorders, Fifth Edition (DSM-5) 33 and the 
International Classification of Diseases, Tenth Revision (ICD-10) 34, psychosis is not a single 
disorder but rather a spectrum 35,36 categorized by a set of key commonly observed features37, 
specifically “common and functionally disruptive symptoms of many psychiatric, 
neurodevelopmental, neurologic and medical conditions(p715)” 38. A number of disorders fall 
within the psychotic spectrum, with the most commonly observed disorders being classified as 
primary psychotic disorders. Primary psychotic disorders exhibit psychosis as the defining 
feature, with disorders including schizophrenia, schizoaffective disorder, delusional disorder, 
schizophreniform disorder and brief psychotic disorder 38. However, an episode of psychosis can 
also be observed in other psychiatric conditions such as major depressive disorder and bipolar 
disorder. Within these disorders, psychotic symptoms such as hallucinations and delusions may 
occur during manic or depressive phases 38. Disorders along the psychosis spectrum differ from 
each other by the type, number, and severity of psychotic symptoms present 38. Disorders that 
fall closer to the psychotic side of the spectrum would be schizophrenia spectrum disorders, 
otherwise considered primary psychotic disorders, whereas disorders that fall closer to the 
affective side would be bipolar disorder or major depressive disorder where psychotic symptoms 
are secondary to the main affective symptoms consistent with their diagnosis 3-5. This concept of 
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psychosis as a spectrum rather than a single disorder with a set of strict clinical criteria is 
consistent with population samples in which a large number of individuals report symptoms of 
psychosis, however they fail to meet the criteria for the clinical diagnosis of a psychotic disorder 
such as schizophrenia 36. Given that psychosis is best represented as a spectrum, with a number 
of diagnoses being placed along this spectrum, it is possible for diagnoses and the presentation of 
symptoms to evolve over time. This thesis draws on the data of participants who have accessed 
care in an early intervention program for psychosis with the majority of participants carrying a 
diagnosis of a primary psychotic disorder, including schizophrenia, schizoaffective disorder, and 
psychosis not otherwise specified, with a smaller subset of participants diagnosed with bipolar 
disorder with psychotic features or depression with psychotic features.  
 
2.1.2 Causes of Psychotic Disorders 
Although no direct cause has been identified, there are a number of potential risk factors that 
have been identified to increase the likelihood of developing psychosis. A developmental 
component has been stated, with models positing that genes involved in neurodevelopment 
and/or early environmental insults may lead to aberrant brain development, predisposing one to a 
later onset of psychosis6. More recent theories have included the role of social determinants in 
the development of psychosis, including factors such as childhood adversity, social isolation, and 
migration 6,39. Other possible risk factors identified include alcohol and drug misuse, social 
stress, cognitive deficits, childhood trauma, underlying mental illness and other medical 
conditions (ex. lupus)6.  
 
2.1.3 Symptom Classification 
In diagnosing psychotic disorders such as schizophrenia, a range of commonly presented 
symptoms are assessed. Both the DSM-5 and the ICD-10 diagnostic manuals, the two primary 
diagnostic manuals used to define and diagnose mental disorders, recognize schizophrenia as 
being comprised of features known as positive and negative symptoms7-9. Positive symptoms are 
categorized by the presence of hallucinations, delusions, and disorganized or bizarre thought 
patterns10. These are collectively referred to as positive symptoms due to them being ‘present’ or 
‘added on’ to typical behavior 11. Hallucinations consist of sensory experiences with which one 
can see, hear, taste, feel, or smell something without the corresponding external stimulus 38, and 
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delusions include pervasive false beliefs that are not based in reality 38,40. In contrast, negative 
symptoms refer to a reduction or loss of function 11 and consist of blunted affect, alogia, 
avolition, anhedonia, and asociality. Blunted affect refers to reductions in emotional expression 
via facial expressions or tone of voice whereas alogia is defined by a reduction in speech 10,41. 
Anhedonia refers to a diminished capacity to experience pleasure, regarded as a core feature of 
schizophrenia 41.Asociality is defined as a reduction in social initiative and an increase in social 
withdrawal due to decreased interest in forming relationships 10,41 whereas avolition refers to a 
marked reduction in motivation and motivational behavior 10,11,35. These symptoms can vary in 
number and severity depending on the person and their diagnosis. The combination of these 
symptoms results in distorted perceptions of reality, and people with lived experiences of 
psychosis describe experiences of unshared perceptions, paranoia, and a loss of sense of having a 
coherent self 1. 
 
2.1.4 Epidemiology and Burden of Illness of Psychotic Disorders 
A first episode of psychosis is typically experienced in between late adolescence and early 
adulthood, a period marked by numerous changes both personally and 
academically/professionally 6. The onset of psychosis has been found to often result in an 
increase in social isolation and detachment from community and peers, discontinuation of 
hobbies and school, and impairment in work related activities directly impacting long-term 
wellbeing. As a result, an episode of psychosis can be highly disruptive to a person’s life and 
negatively impact their growth and development.  
 
The lifetime prevalence of all psychotic disorders has been estimated to be between 3.06% and 
3.48% in the general population42. The most commonly occurring psychotic disorder, 
schizophrenia, has an estimated lifetime prevalence of between 0.4% and 0.9% within the 
general population42-45, low in comparison to other common mental disorders such as major 
depression, with an estimate of around 27%46. However, despite its relatively low prevalence, 
schizophrenia and other psychotic disorders result in a significant burden to both the healthcare 
system and the economy. Schizophrenia is amongst the top 25 leading causes of disability 
worldwide and people with psychotic illness have an increased risk of premature mortality when 
compared to the general population 47. This increase in mortality is due to an increased risk of 
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suicide along with the numerous co-occurring medical conditions found to be associated with 
schizophrenia, as well as the under-detection and under-treatment of these medical conditions 47. 
 
Financial costs associated with schizophrenia are higher in comparison to other chronic mental 
and physical health conditions, with both the direct costs to the healthcare system as well as the 
indirect costs due to loss of productivity, social service needs, and possible criminal justice 
involvement 47,48, resulting in an estimated annual cost of $6.85 billion CAN 48.  
 
2.2 Negative Symptoms in Psychotic Disorders 
2.2.1 Historical Overview 
As previously stated, negative symptoms consist of processes that are unusual in their reduction 
or absence and may result in a decline in function 1,11,41. Schizophrenia has been defined as an 
illness of early and progressive degeneration, with negative symptoms representing the illness’ 
core and possibly the most significant contributing factor in the impaired functioning 
experienced by people with psychosis 49. Early descriptions of schizophrenia (1917/1919) 
emphasized a disturbance of volition or will as the fundamental underlying process in its 
pathology 50,51. 
 
However from the 1950s up until the 1980s, the treatment of schizophrenia was mainly focused 
on the alleviation of positive symptoms, namely through the introduction of antipsychotic 
medications 52. The distinction between negative and positive symptoms re-introduced by 
Andreasen in the 1980s marked the beginning of modern research on the subject53. This brought 
about further research and debate on whether the two domains were distinct syndromes. Crow 
was one of the first to distinguish between negative and positive syndromes, indicating that they 
were syndromes independent of one another and with differing etiologies and prognoses54. 
Typically, patients exhibiting predominantly positive symptoms were characterized by good 
premorbid functioning, relatively favorable outcomes, acute onset, good response to treatment, 
and hyperdopaminergic activity. In contrast, patients exhibiting predominantly negative 
symptoms were characterized by poor premorbid functioning, impaired cognition, poor response 
to treatment, and structural brain abnormalities 54. More recent factor analyses using measures of 
psychotic symptoms have found support for three-factor, five-factor, and even eleven-factor 
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models of psychotic symptomology9,55. These findings have indicated symptom categories in 
addition to positive and negative symptoms, such as disorganization symptoms, depression, and 
anxiety; however, all possible models currently proposed included both positive and negative 
symptoms as separate and distinct factor domains. Negative symptoms, in particular, have 
consistently been found to load onto a factor separate from positive symptoms, disorganized 
symptoms, and affective symptoms, and results from these studies have provided support for the 
distinctiveness of negative symptoms and its recognition as being an independent target for 
treatment 9. 
 
2.2.2 Current Conceptualization 
The current conceptualization of negative symptoms consists of blunting of affect (i.e. reduced 
emotional expression), poverty of speech (i.e. alogia), asociality (i.e. apathy or social 
withdrawal), avolition (i.e. lack of drive or motivation), and anhedonia (i.e. lack of or diminished 
interest, enjoyment, or pleasure from activities) 44,52,56. For example, individuals experiencing 
negative symptoms such as blunted affect and/or alogia may seem artificial or mechanical in 
movements, with few instances of spontaneous movement, eye contact, or facial expression 57. 
Conversations may seem emotionless with few changes in vocal pattern or inflections 57. 
Experiences of avolition may be observed through a lack of initiative or self-directed behavior, 
whereas others may view the individual as being socially withdrawn or without a sense of caring 
57. Recent research on negative symptoms have also proposed that the symptom domain may be 
better represented using a two-factor model, with one factor being ‘diminished expression’ 
(consisting of blunted affect and alogia) and another being ‘diminished experience/amotivation’ 
(consisting of avolition, anhedonia and apathy) 8,9,30,35,44,49,58-60. As described by Foussias and 
Remington, the diminished experience category involves disturbances of involvement with the 
surrounding environment, observed via deficits in drive and pleasure, whereas the diminished 
expression category addresses issues regarding expressivity, observed via deficits in affect and 
speech49. Outcome differences between both domains have been observed among persons with 
schizophrenia. The diminished expression domain being associated with an earlier onset, 
diminished cognitive traits and a lower level of education while the diminished experience 
domain is related to duration of untreated psychosis (DUP), family history of psychosis, work 
status and global functioning59. However, issues regarding the relationship between negative 
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symptoms subdomains are still present. Along with research showing differential factor loadings 
between the diminished expression and diminished experience domains, these domains also 
exhibit a moderate interrelationship, with inter-factor correlation coefficients between 0.47 and 
0.57 49. Analyses of the Scale for the Assessment of Negative Symptoms (SANS) have also 
demonstrated moderate interrelationships for affective flattening and anhedonia-asociality 
subscales (r=0.49 and 0.48, respectively) as well as between alogia and avolition and anhedonia-
asociality (r=0.61 and 0.53, respectively) 49. These findings would seem to suggest that although 
these domains have distinct phenomenological entities, that they may reflect a common 
underlying etiology.  
 
In comparison to positive symptoms, negative symptoms are often associated with a more 
chronic and deteriorating course of illness, with the symptoms persisting even after positive 
symptoms have been treated and largely reduced 13,44,61,62. Evidence suggests that negative 
symptoms contribute to more impaired quality of life and poorer functioning than positive 
symptoms 22,24,26,63,64. However, negative symptoms are often not as easily observable and are 
harder to identify, unlike positive symptoms which are more easily viewed and are often the 
most prominent and troubling symptoms present at the onset of psychosis. For reasons such as 
these, positive symptoms were once considered the main defining feature of psychosis and 
therefore much research was conducted on positive symptoms being a treatment target of 
psychosis. Only recently have more studies been focused on negative symptoms and their impact 
on disease progression and outcome. 
 
2.3 Recovery from Psychotic Disorders 
2.3.1 Symptomatic vs. Functional Recovery 
Although current approaches, such as pharmacological interventions, have aided patients in 
achieving some form of symptomatic recovery, it is now understood that recovery from serious 
mental illness includes both symptomatic recovery and functional recovery. Symptomatic 
recovery refers to sustained improvement in symptoms of psychosis, whereas functional 
recovery refers to sustained improvement in social and vocational functioning 15,19,65. Functional 
capacity, defined as the ability to perform tasks and activities necessary in daily life, is often 
significantly impaired in both the acute and non-acute phases of psychotic illness 15,19,66. Around 
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75% of people with a first episode of psychosis achieve symptomatic remission with 
antipsychotic medications, however, functional recovery is achieved by only by a minority 20. 
Robinson and colleagues found that among a sample of 118 participants diagnosed with 
schizophrenia spectrum disorders, around 57% achieved symptomatic remission for 2 years or 
longer, whereas only 38% achieved adequate functioning and 14% achieved full 
recovery67.Similar findings have been demonstrated by other studies 68,69. With functional 
recovery found to lag behind clinical remission, impairments in functional capacity have been 
recognized as a major barrier to full recovery among people with primary psychotic disorders20.  
 
2.3.2 Negative Symptoms and Functional Outcome 
In recent years, studies have assessed functioning among people with schizophrenia to determine 
factors that are strongly associated with poor functional outcomes. Negative symptoms have 
been shown to contribute more to impaired functioning than other symptom domains 24,26,66,70. 
Rabinowitz and colleagues conducted a study in which they attempted to discern the relative 
effect of negative symptoms on functioning, in comparison to other symptom domains24. They 
found that both baseline functioning and changes in functioning over time were most strongly 
related to negative symptoms, suggesting that functioning and the improvement of functioning is 
most strongly related to negative symptoms. 
 
This association between negative symptoms and functional outcomes has consistently been 
replicated across a broad range of patient populations, including both first-episode and chronic 
psychosis 66. Specifically, studies have shown negative symptoms to be highly correlated with 
impairments in occupational functioning, household integration, relationships, and recreational 
activities 70,71. Fervaha and colleagues assessed the impact of primary negative symptoms on 
functional outcomes, controlling for other psychopathological factors such as positive symptoms, 
depression, and anxiety26. Findings showed that even when controlling for these symptoms, 
negative symptoms were a significant contributor to the functional impairment seen in patients 
with schizophrenia. As well, negative symptoms were found to explain a large portion of the 
variance in functional status, even after the variance associated with other clinical variables (e.g. 
depression, anxiety, positive symptoms, extra-pyramidal symptoms) had been accounted for. 
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Results such as these have highlighted the central role of negative symptoms in functional 
outcome.   
2.3.3 Avolition and Functioning 
With the understanding that negative symptoms are significantly associated with functional 
outcomes – more so than any other symptom domain in psychosis – research has shifted towards 
understanding the connection between negative symptoms and functional outcomes. Given that 
negative symptoms can be classified into separate subdomains, the impact that each of these 
domains has on functional outcomes has been investigated.  Among the five symptoms that fall 
under the category of negative symptoms, the amotivation subdomain has consistently been 
found to have the strongest association with functional outcomes.  
 
Foussias and colleagues conducted a study assessing each separate subdomain of negative 
symptoms and its contribution to functional impairment25. Among adult outpatients diagnosed 
with schizophrenia, they found that the amotivation subdomain of the SANS, consisting of 
avolition, anhedonia and asociality, was the sole predictor of functioning accounting for 
approximately 74% of the variance in current functioning25. This finding was confirmed in 
separate studies using the Apathy Evaluation Scale, a measure of avolition, with similar results 
29,72. To determine whether motivational deficits were strong contributors to poor functioning, 
Foussias and colleagues extended past research by assessing the concurrent contributions of 
motivational deficits in addition to other negative symptoms and other symptom domains at 
baseline on functional outcomes longitudinally73. In a sample of 18 participants diagnosed with 
schizophrenia, they found that amotivation was the most influential predictor of functioning, at 
baseline as well as at six-month follow-up; with amotivation accounting for 74% and 72% of the 
explained variance in functioning, respectively 25,73. In follow up to this study, a 2014 study by 
Fervaha and colleagues assessed 754 patients with schizophrenia to determine associations 
between selected clinical variables and one-year functional outcomes71. Their analyses identified 
several independent predictors, with the strongest being amotivation and neurocognition. A 2015 
study by Fervaha and colleagues, assessing the prevalence of motivational deficits and their 
impact on community functioning among 166 early intervention participants with a diagnosis of 
schizophrenia, found that motivational impairments were found in more than 75% of 
participants22. Furthermore, these deficits were the most robust and reliable predictor of 
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functional outcomes at baseline and longitudinally, with an independent predictive value that no 
other assessed variable exhibited22. 
 
Chang and colleagues conducted a study to examine the direct effect of avolition and other 
clinical variables at baseline on one-year functional outcomes in a cohort of people with 
schizophrenia27. A number of significant factors were identified to be correlated with functional 
outcome at 12 months, including amotivation. However, multiple regression analyses revealed 
that the amotivation subdomain and cognitive composite scores were the only independent 
factors associated with functioning at 12 months, with amotivation being the most robustly 
associated with functioning even after adjusting for cognition, additional negative symptoms, 
and other symptom dimensions 27. In a 2015 study by Minchinio and colleagues, the participants 
categorized as low functioning all exhibited higher levels of negative symptoms, with avolition 
found to be independently associated with functional outcome 23. Amotivation has also been 
associated with level of social activity and social outcomes, such as marriage and gaining 
competitive employment 74. In fact, studies have been able to clearly separate people based on 
their presentation of ‘diminished expression’ (DE) vs ‘diminished experience’ (AA) symptom 
severity, with people with high AA severity experiencing worse functioning in all domains, in 
addition to more frequent hospitalizations, worse overall psychosis, and social anhedonia 30,70,75. 
 
2.4 Issues in Measurement 
Although research has identified negative symptoms, specifically those under the amotivation 
subdomain, as being highly associated with functional outcomes, there are concerns regarding 
the validity of these findings based on the measures used to assess these variables.  
 
2.4.1 Measurement of Negative Symptoms 
Certain criteria should be met for proper measurement of negative symptoms. Such measures 
should: (i) assess all domains of negative symptoms while excluding other symptom domains; 
(ii) be sensitive to change; (iii) demonstrate good reliability; and (iv) be relatively brief for 
administration purposes 76. Most importantly, the measures should assess the symptom itself, 
rather than an outcome of that symptom 76. However, current measures of negative symptoms 
differ based on their inclusion of negative symptom subdomains. Two of the most widely used 
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scales, the Scale for the Assessment of Negative Symptoms (SANS) and the Positive and 
Negative Syndrome Scale - Negative Subdomain Scale (PANSS), have a substantial degree of 
overlap, but also exhibit significant differences. These scales, in addition to other negative 
symptom severity measures, differ in their coverage of the 5 negative symptom domains. As 
previously mentioned, the current consensus on negative symptoms views the domain as being 
composed of avolition, anhedonia, asociality, alogia and blunted affect 45,52.56. Among the 
measures assessed, only the SANS covers all 5 domains. However, the SANS also includes the 
domain of inattention, a factor that is no longer considered to be a negative symptom but rather a 
symptom of the disorganization symptom domain. The SANS also combines anhedonia and 
asociality, two separate negative symptom categories, into a single domain 77. The PANSS 
negative symptom subscale contains items outside the currently viewed negative symptom 
domains 77. Given that our current understanding of the relationship between the amotivation 
subdomain and functional outcomes is reliant on these measures, it is important to examine the 
specific factors assessed using these tools.  
 
2.4.2 Overlap in Measures of Avolition and Functioning 
Our literature review has shown that the amotivation subdomain, consisting of avolition, 
anhedonia and asociality, is the strongest predictor of functional outcomes in individuals with 
schizophrenia. Currently, the most commonly used measure of avolition is the SANS 
amotivation subdomain. But this measure, in addition to other measures of avolition, has a 
degree of conceptual overlap with measures of functional outcomes due to how avolition is 
assessed. Measures such as the SANS have items related to avolition that are rated mostly based 
on behavior and therefore do not take into account the intrinsic and subjective experiences of 
motivation, which may be intact but not directly observable due to other factors 78. When looking 
at the avolition subdomain of the SANS, items assess behavior such as personal grooming habits, 
with the participant being graded based on the following statement “The patient’s clothes may be 
sloppy or soiled, and he or she may have greasy hair, body odor, etc.” (Appendix B). An 
assessment of motivation is therefore made based on the individual’s physical appearance, 
assuming that a motivated individual would present themselves differently. However, overt 
behavioral markers such as personal grooming habits are also included as a marker of functional 
outcome. The Role Functioning Scale (RFS)79 is a scale used to measure functional outcomes 
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based on four main functioning domains: working productivity, independent living and self-care, 
immediate social network, and extended social network. As seen in the RFS Independent Living 
and Self-Care subdomain (Appendix C), functioning is assessed based on an individual’s ability 
to manage and care for their home and self, with raters making decisions of functional ability 
based on whether the participant maintains personal grooming and hygiene habits in addition to 
feeding themselves and maintain the cleanliness and upkeep of their household. This overlap in 
assessment markers can be observed in other avolition statements such as the “Impersistence at 
Work or School”, which states that the person has difficulties seeking or maintaining work, 
education, or other meaningful activity. However, assessing the outcome of employment or 
education does not necessarily measure one’s motivation to gain employment or education, 
which could be hindered due to other factors including systemic barriers such as the stigma 
around mental illness 80,81. In fact, this statement more accurately aligns with measures of 
vocational functioning, as seen in the Role Functioning Scale Working Productivity subdomain. 
As well, the avolition subdomain assessed using these measures have a limited number of items 
and therefore this may contribute to the inaccurate measurement of avolition. The SANS only 
includes three separate markers of avolition, two of which we have shown to overlap 
significantly with measures of functioning.  
 
Measurement issues can also be found within the anhedonia-asociality subdomain of the SANS. 
Of the four statements used to assess one’s severity of anhedonia, two focus on sexual activity, 
with statements that the individuals may show a decrease sexual interest, activity or enjoyment 
and that the person may be unable to form intimate relationships with either the opposite sex or 
with family. However, one’s current sexual activity does not necessarily indicate one’s level of 
anhedonia. In other words, measuring one’s level of pleasure does not necessarily measure one’s 
objective capacity for experiencing pleasure 82, with other factors possibly playing a role in the 
ability to form a sexual/intimate relationship, regardless of whether they themselves want to 
enjoy said relationship. As well, item 21 asks about the number of friends that the individual has, 
with a lack of friends being related to a proposed preference to spend time alone. This purports 
that a lack of a large friend network is consistent with a lack of pleasure gained from friendship, 
regardless of whether the person wants a larger social group or whether in fact they fail to gain 
pleasure from friendships. These SANS anhedonia-asociality items do not directly measure one’s 
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ability to experience pleasure but rather the observed behavioral outcomes assumed to be 
associated with the ability to experience pleasure, as seen in the SANS avolition subdomain 
statements 
 
The validity of current measures of negative symptoms, with an emphasis on 
avolition/amotivation subdomains, raises concerns regarding the current evidence base. Here we 
discussed the SANS specifically, however other measures of avolition currently used 
demonstrate these issues. Past literature has been consistent in their findings of associations 
between avolition and functioning, however these associations were drawn from measures that 
are limited in their operationalization of negative symptomology. When considering validity, 
these measures focus on measuring the outcome of the construct rather than the construct itself; 
demonstrating issues in regard to the translation of the symptom constructs into operational 
measures 83,84. Construct validity, being the degree to which a measure assesses the construct it 
claims to be measuring, would therefore be questioned because the items proposed to measure 
avolition do not assess motivation but rather the behavior assumed to be indicative of motivation 
84. When we look specifically at the content of the items proposed to measure these symptom 
domains, as seen through the SANS, we see that there are also limitations in how conclusive 
these measures are in assessing the construct. External observable characteristics are focused 
upon without the assessment of more internal, psychological markers of motivational drive. With 
these validity concerns present in measures of negative symptoms in mind, the proposed 
relationship between avolition and functioning becomes harder to assess. Given that there is a 
limited number of measures that assess avolition, and that current measures demonstrate these 
issues in regard to construct validity, there is a need to address more intrinsic aspects of 
motivation in regard to their impact on functional outcomes to further elucidate the relationship 
between amotivation and functional outcomes. 
 
2.5 Motivational Drivers and Functional Outcomes in Psychosis 
2.5.1 Search Strategy 
To identify intrinsic factors that drive motivation, we searched through PsycINFO, EMBASE, 
and Medline to identify articles examining the association between motivational deficits and 
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functioning among individuals with psychotic disorders. Articles examining theories regarding 
motivation, avolition, and negative symptoms were assessed.  
 
2.5.2 Cognitive Model of Negative Symptoms 
Until recently, little attention had been given to understanding the possible role that motivational 
variables have in the development and maintenance of negative symptoms. However, research 
regarding the effects of cognitive behavioral therapy (CBT) for people with psychotic disorders 
have found that negative symptoms can be targeted in therapy by focusing on factors such as 
dysfunctional attitudes, coping style, and self-efficacy 85.  
 
Proposed by Rector, Beck and Stolar, the cognitive model of negative symptoms is a theory 
regarding the expression and maintenance of negative symptoms 86. Specifically, the model 
proposes that people with schizophrenia often experience cognitive impairments that may hinder 
their normal adjustments in social and academic/occupational domains, thus contributing to poor 
academic achievement, work performance, and social problems 86,87. These deficits in social and 
occupational functioning therefore lead to the formation of dysfunctional attitudes about one’s 
abilities, which in turn can reduce one’s motivation or engagement in goal-directed behaviors.  
 
Furthermore, this reduction in engagement and withdrawal from tasks serve as maladaptive 
techniques employed to avoid expected poor performance and/or failure. In turn, these 
maladaptive techniques strengthen dysfunctional beliefs by limiting one’s ability to participate in 
future goal-directed tasks, which may have counteracted poor past experiences. In line with this 
theory, it has been proposed that negative symptoms may develop as a result of this cycle of 
negative cognitive appraisals regarding one’s self, formed as a response to “threatening 
delusional beliefs, perceived social threat, and anticipated failure in tasks and social activities” 86.  
Functioning may then become further impaired with the development and maintenance of 
negative symptoms.  
 
The model proposes that there are four negative expectancy appraisal domains considered to be 
characteristic of negative symptomatology in psychotic disorders that contribute to the 
expression and maintenance of negative symptoms. These four domains include having low 
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expectancies for pleasure, low expectancies for success, low expectancies for acceptance, and a 
perception of limited resources.   
 
Low expectancies for pleasure can be explained as the expectations that people with 
schizophrenia often have that they will not gain or will gain very little pleasure for their efforts at 
a given activity. Current research supports the theory that people with schizophrenia, in 
comparison to non-patient controls, do experience more negative emotions and fewer positive 
emotions in daily life, as well as portraying significantly fewer positive and negative facial 
expressions in response to emotional stimuli. However, their ability to experience a full range of 
emotion is intact, with research showing that this perhaps is a function of their participation in 
fewer activities that are likely to elicit pleasant emotions 86. 
Figure 2.1 The Cognitive Model of Negative Symptoms86 
 
Low expectancies for success refer to the poor confidence that people with schizophrenia may 
have in their ability to perform tasks, and the belief that their performance and abilities are 
subpar in instances in which they successfully perform tasks 86. This negative viewpoint affects 
their motivation to initiate and follow through with goal directed behaviors 86. This low 
expectancy for success has been identified to be a significant factor in the maintenance of 
negative symptoms, with individuals’ expectancies for success being positively correlated with 
negative symptom severity 88. 
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The domain of low expectancies for acceptance refers to the impact that stigma can have on a 
person’s motivation and behavior, with previous studies extensively describing the adverse 
impact of a schizophrenia diagnosis 86. This may be compounded by symptom distress and 
misconstruals by others regarding reasoning behind behavior or lack thereof, that all may lead to 
negative beliefs about self-worth.    
 
Finally, the perception of limited resources appraisal domain refers to the dysfunctional beliefs 
held by people with schizophrenia about the costs associated with applying energy and effort, 
which can lead to passivity and avoidance of activities that require effort 86. This belief in a lack 
of available resources however may be a symptom of psychosis itself, given that a number of 
studies have found people with schizophrenia possess a diminished cognitive ability for task 
relevant cognitive operations. However, this lack of ability may also be exaggerated due to an 
inflexible and often pessimistic cognitive view 85.  
 
The cognitive model of negative symptoms demonstrates the psychological influences, or 
drivers, that can increase or diminish one’s motivational drive. Negative expectancy appraisals 
regarding a person’s ability to gain pleasure, experience success, experience acceptance, and to 
gain and develop resources to achieve one’s goals can lead to reductions in motivation and 
engagement in both goal-directed behavior and other enjoyable activities, resulting in social 
withdrawal and lack of motivation 89.  
 
Use of and support for the cognitive model of negative symptoms has been found in both cross-
sectional and longitudinal studies 87,88,90-98. A number of studies have found associations between 
increased dysfunctional attitudes, such as defeatist performance beliefs, and negative symptoms 
in samples of people with schizophrenia 89.  Importantly, these associations have been found 
even after controlling for other symptom domains, such as depression 22,97.   
 
2.6 Drivers of Motivation 
Although research on specific motivational deficits among people with psychotic disorders is 
sparse, we identified a number of studies and theories discussing possible processes involved in 
motivational drive, as well as a few studies assessing these processes in regard to negative 
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symptoms. Motivation has been found to be reliant on a number of processes, revolving around 
the ability to anticipate rewards, the hedonic experience of rewards, and the ability to form and 
sustain a mental representation of rewards and work towards that future reward by modifying 
one’s behavior.  Through the use of Rector, Beck, and Stolar’s cognitive model of negative 
symptoms and our review of the current evidence base, we identified three psychological factors 
found to influence motivational drivers. 
 
2.6.1 Self-efficacy 
Self-efficacy has been defined by psychologist Albert Bandura as the extent to which we believe 
ourselves capable of successfully performing a given task to produce a desired outcome99. 
Perceived self-efficacy refers to an individual’s belief in his or her ability to influence events that 
affect the outcome of his or her life 28. Given that self-efficacious beliefs determine how a person 
thinks, feels, and behaves, they play a key role in the self-regulation of motivation 99. As belief in 
one’s own ability to succeed in tasks is influenced by one’s perceived self-efficacy, it contributes 
to the amount of time and effort that one will expend to complete a task, in addition to the 
number of obstacles or setbacks tolerated before giving up 94. Self-efficacy beliefs therefore are 
thought to be important driving factors in one’s goal setting, willingness to expend effort and 
persist at a given activity, and one’s resilience to failure 99.   
 
Self-efficacy beliefs influence one’s causal attributions – people who regard themselves as 
highly efficacious attribute their failures to insufficient effort, whereas those who believe 
themselves to be inefficacious attributing their failure to their own low ability 99. These causal 
attributions affect our level of motivation, our performance, and our affective reactions. People 
who have a low perceived self-efficacy avoid or forego certain tasks which may reinforce their 
own low expectations, whereas people with a high perceived self-efficacy may be more likely to 
view difficult tasks as challenges that they can achieve and learn from 99,100. Although self-
efficacy is viewed as a determinant of behavior, it is also possible that one’s experiences of 
success due to their own behavior can influence self-efficacy beliefs, suggesting that there may 
be a bi-directional relationship between self-efficacy and behavior 99. This is important to note, 
given that it would suggest that self-efficacy beliefs are not stagnant and can actively change 
given one’s experiences of goal achievement or failure. 
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Among individuals with schizophrenia, in both acute and chronic phases of illness, self-efficacy 
is reduced in comparison to controls 28,89,101. However, findings have been mixed with respect to 
the relationship between self-efficacy and negative symptoms in schizophrenia spectrum 
disorders. Numerous studies have found associations between greater self-efficacy and lower 
negative symptom severity among people with schizophrenia spectrum disorders 
28,85,89,90,94,95,102,103. A study by Cassar and colleagues used the cognitive model of negative 
symptoms to assess possible influences on negative symptom development and maintenance94. 
Their findings suggest that low self-efficacy might potentiate negative symptoms, mainly 
anhedonia and avolition, through a reduction in expectations of success, efforts to obtain 
rewards, confidence in one’s cognitive skills, and a reduced tolerance toward goal obstacles and 
aversive experiences. However, it is also important to note that a number of studies have failed to 
find a significant relationship between the two variables 96,100,102,104-107. Couture and colleagues 
assessed a number of dysfunctional beliefs in relation to the cognitive model of negative 
symptoms, with self-efficacy included as a measure of negative expectancy appraisals of one’s 
self; however, the authors failed to find a relationship between self-efficacy and negative 
symptoms96.  
 
Given the proposed link between negative symptoms, namely avolition, and functional 
outcomes, it is possible that a relationship between self-efficacy and functional outcomes also 
exists, given that self-efficacious beliefs are a component of motivation. One might expect that 
self-efficacy would be the most strongly related motivational driver to the negative symptom 
subdomain of avolition, and interventions targeting self-efficacy would be useful for alleviating 
avolition and thereby improving functional outcomes. However, few studies have assessed the 
role of self-efficacy and functioning in schizophrenia. Pratt and colleagues assessed the role of 
self-efficacy as a mediating link between negative symptoms, cognition and premorbid 
adjustment, and functioning as measured by psychosocial status among patients diagnosed with 
schizophrenia or schizoaffective disorder103. Results showed that although self-efficacy was 
found to have a small but significant correlation with premorbid adjustment, negative symptoms, 
and functioning, there was no evidence to suggest that self-efficacy mediated the relationship 
between these factors103. Specifically, self-efficacy did not mediate the relationship between 
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premorbid adjustment or negative symptoms with functioning. However, they did find evidence 
to suggest that negative symptoms mediated the relationship between self-efficacy and 
functioning103.  
 
A study by Kurtz and colleagues built upon these findings by investigating whether self-efficacy 
mediated the relationship between key illness features, such as negative symptoms and cognition, 
and performance-based measures of functioning102. There was no association between self-
efficacy and functional skills, however they did find a moderating effect of illness insight for the 
relationship between self-efficacy and functioning, where at higher levels of insight, self-efficacy 
beliefs were linked to measures of functioning. This finding was not present among people with 
low insight, providing a possible explanation as to why self-efficacy beliefs, which have been 
shown to play a positive role in achievement outcomes of healthy populations 99, have less of a 
role in mediating the relationship between key illness features and functioning in schizophrenia. 
Studies assessing the mediating role of negative symptoms in the relationship between self-
efficacy and functioning have been mixed as well, with some lending support to the mediating 
role of negative symptoms 28,93 whereas others have failed to find a mediation effect 95. 
 
2.6.2 Defeatist Performance Beliefs 
As the discussion on motivational deficits and their role in the negative symptoms of 
schizophrenia has grown in recent years, defeatist performance beliefs (DPB) have received the 
most empirical support and been consistently found to be associated with negative symptom 
severity and functional outcomes 87. DPB refers to a specific form of defeatist beliefs that 
consists of overgeneralized negative conclusions about one’s ability to perform tasks 87. 
Consistent with the cognitive model of negative symptoms, defeatist performance beliefs are 
considered to fall under the category of dysfunctional attitudes, in which people perceive 
themselves to exhibit inferior task performances. These defeatist beliefs form maladaptive 
strategies that protect the individual from expected pain and rejection, however they also form 
barriers for individuals to engage in constructive activities 98.  
 
DPB regarding the planning and execution of tasks can prevent initiation and engagement in 
motivated, goal-directed behavior. Although the role of DPB in schizophrenia has been 
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investigated only recently, past research generally focused on the role of dysfunctional attitudes 
as a general mechanism underlying motivational and pleasure deficits in people with affective 
disorders. Beck and colleagues built upon this work with the development of the cognitive model 
of negative symptoms, positing that the development of DPB result in a decreased motivational 
drive which may contribute to the decline in functional outcomes in schizophrenia 91. 
Specifically, Beck and colleagues theorize that DPB leads people with schizophrenia to a false 
sense of safety, whereby one succumbs to the defeatist beliefs and forms dysfunctional attitudes, 
and consequently lessen the likelihood of goal-directed behavior further reinforcing their 
disengagement from society.  
 
Negative performance beliefs have been endorsed by individuals with chronic schizophrenia to a 
greater extent than healthy controls and have also been found to be associated with negative 
symptoms 28,98,108. In relation to self-efficacy as a motivational driver, DPB and self-efficacy 
have been found to exhibit a moderate inverse correlation to one another, along with each being 
significantly associated with negative symptoms when adjusting for one another 89. Cross-
sectional studies have found that the occurrence of DPB are associated with elevated cognitive 
impairments such as deficits in working memory and verbal learning, as well as increased 
negative symptom severity 96,97. This positive correlation between DPB and negative symptoms 
is found to be independent of positive symptoms, as well as depressive symptoms which are 
often found to be closely tied to negative symptomology 28,96,97. Importantly, this relationship 
between DPB and negative symptoms is seen to a larger extent with negative symptoms 
associated with motivation and pleasure, such as avolition and anhedonia 28,91. A 2011 study by 
Couture and colleagues found that when assessing the relationship between DPB and negative 
symptom domains, a significant relationship was only observed in regard to the ‘diminished 
experience’ domain, referring to the negative symptoms of avolition, anhedonia, and asociality, 
thus lending credence to the theory that DPB play an important role in motivational drive96.  
 
Research is limited on the relationship between DPB and functional outcomes. Some studies 
have found an association between increased reports of DPB and reduced functioning in people 
with schizophrenia. Ventura and colleagues assessed the relationship between dysfunctional 
attitudes, including defeatist beliefs, and negative symptoms and found them to be significantly 
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correlated with daily functioning, with negative symptoms found to mediate the relationship28. 
This association was also demonstrated by Kiwanuka and colleagues 109. As well, Grant and 
Beck found an increase in defeatist beliefs to be associated with greater negative symptom 
severity, reduced functioning, and decreased neurocognitive performance97. When assessing the 
mediational role that DPB may play, they found that DPB were mediators in the relationship 
between negative symptoms and functioning. In a study assessing the use of cognitive therapy at 
targeting dysfunctional attitudes, Pillny and Lincoln found that a reduction in DPB was 
associated with a change in functioning 18 months after treatment, and that the use of cognitive 
therapy to target dysfunctional attitudes was effective in improving motivation and functioning 
among a sample of individuals with persistent negative symptoms 92. 
 
Although empirical evidence suggests that DPB and functioning are associated, whether they are 
mediators in the relationship between negative symptoms and functioning, or rather are mediated 
by negative symptoms, is still unclear. Although other cognitive and emotional mechanisms of 
negative symptom development and functional outcome decline have been proposed, early 
evidence suggests that targeting DPB has the potential to reduce negative symptoms and improve 
functional outcomes 91. Campellone and colleagues conducted two meta analyses assessing the 
relationship between DPB and negative symptoms and functional outcome in people with 
schizophrenia91. Findings demonstrated a small effect size for the relationship between DPB and 
negative symptoms, as well as between DPB and functional outcome91.  
 
2.6.3 Anticipatory Pleasure Deficits 
Anhedonia has been defined as a diminished capacity to experience pleasant emotions, as well as 
a difficulty in experiencing pleasure 49. It is a clinically significant aspect of schizophrenia 
falling under the category of negative symptoms and has been found to be relatively stable and 
linked with significant impairment in social functioning 82,110. However, current evidence 
suggests that people with schizophrenia do not experience a full hedonic deficit. Experimental 
studies using a wide range of emotion-evoking stimuli demonstrate that people with 
schizophrenia report intact experiences of emotions, both pleasant and unpleasant, and that these 
experiences of ‘in the moment’ emotion are equal in intensity compared to healthy controls 49,110-
112.  Interestingly, studies employing the use of self-report or interview-rated measures of 
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anhedonia have found people with schizophrenia tend to report lower levels of trait-like hedonic 
experiences 9,110-115. This ‘emotion paradox’ has been assessed by considering what constitutes 
the experience of pleasure. According to Klein (1984), pleasure can be divided into two forms, 
anticipatory and consummatory, whereby anticipatory pleasure involves motivated behavior and 
a desire for a future stimulus whereas consummatory pleasure describes the positive emotion 
experiences at satiation 112,116. The Temporal Experience of Pleasure scale developed by Gard 
and colleagues116differentiates between anticipatory and consummatory pleasure. Through the 
use of this scale, studies have shown that people with schizophrenia experience deficits in self-
reported anticipatory pleasure but not consummatory pleasure 116,117. Furthermore, anticipatory 
pleasure scores were significantly correlated with behavioral activation, response to rewards, 
drive, and assessments of social and family role functioning, whereas consummatory pleasure 
was only found to be correlated with physical anhedonia 112,113,116.Foussisas and Remington 
proposed that people with schizophrenia experience a diminished capacity to anticipate pleasure 
gained by the pursuit or achievement of a goal49. This is indicative of an anticipatory pleasure 
deficit, suggesting that anhedonia in schizophrenia is closely related to both motivation and goal-
directed behavior. Hedonic impairments, therefore, may be considered one facet of motivational 
deficits 82,117, with these findings supporting the two-factor subdomain structure of negative 
symptoms with anhedonia and avolition in psychotic disorders being closely related, forming a 
distinct subdomain separate from other negative symptoms. Specifically, that psychotic disorder 
symptomology includes motivational deficits, with both avolition and anhedonia being 
differential expressions of this common underlying process.  
 
Considering the cognitive model of negative symptoms, anticipatory pleasure deficits would 
align with the cognitive appraisal domain of low expectancies for pleasure. However, studies 
assessing the link between anticipatory pleasure and motivation are limited. In support of the 
theory, findings have shown that people with schizophrenia are poor at predicting enjoyment in 
the distant future and this strongly influences their motivation to seek out a desired outcome 
116,117. As such, these differences in the experience of wanting versus liking (i.e. anticipatory 
pleasure versus consummatory pleasure) may play a strong motivational role in driving 
individuals with psychotic disorders to work towards specific stimuli or experiences. A paper by 
DaSilva and colleagues examining the association between amotivation and hedonic deficits 
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identified a significant correlation between anticipatory pleasure and amotivation82. As well, 
Chan and colleagues found, in comparison to patients with no negative symptoms, individuals 
who exhibited negative symptoms reported experiencing less anticipatory pleasure but did not 
differ in reports on consummatory pleasure118. However, findings from Vignapiano and 
colleagues failed to find an association between low motivation and anticipatory pleasure 
deficits, demonstrating the mixed findings on the proposed relationship119.   
 
There is a paucity of studies on the relationship between anticipatory pleasure deficits and poor 
functioning. Buck and Lysaker found that among a sample of 51 individuals with schizophrenia 
spectrum disorder, anticipatory pleasure scores at baseline were correlated with poor social 
functioning at six-month follow-up, as well as emotional discomfort and positive symptoms, 
however they did not find a correlation between anticipatory pleasure and negative symptoms110. 
However, Mote and colleagues conducted a similar study with findings demonstrating the 
opposite effect; with anticipatory pleasure scores being negatively correlated with negative 
symptoms but no significant relationship with functional outcomes were observed114.  
 
2.7 Knowledge Gap 
Although the current evidence base suggests that negative symptoms play a significant role in 
functional outcomes, specifically via the avolition/anhedonia subdomain, few studies have 
assessed the relationship between functional and psychological drivers of motivation. Instead, 
the majority of the studies assessing functional outcome rely solely on measures of avolition that 
measure overt behavior as a proxy for motivational level. The concern with this approach is that 
rather than measuring the symptoms itself, the behavioral outcome of functional ability is being 
assessed. When reviewing the current evidence base, a number of studies were found that 
assessed motivational factors such as self-efficacy, defeatist performance beliefs and anticipatory 
pleasure deficits. However, these studies were mainly descriptive in nature and did not control 
for a full range of potential confounding factors. The few studies that did perform multivariable 
analyses did not take in to account a wide range of covariates or potential confounders and 
instead focused mainly on symptom variables, such as positive symptoms and depression. 
Furthermore, these studies assessed one or two of the identified drivers of motivation, with a 
different sample being used with each study. Studies comparing these drivers of motivation and 
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the role they play in regard to functional outcomes within the same sample have not been 
conducted. Therefore, our current knowledge on the relationship between motivational drivers 
and functioning does not consider the role or contributions that other psychosocial and clinical 
variables may have. 
 
Additionally, these prior studies often included measures of negative symptoms within their 
multivariable models, specifically the negative symptoms that fall within the diminished 
experience subdomain, which overlap significantly with measures of functioning. As well, a 
number of these studies assessed the role of the identified drivers of motivation in regard to their 
indirect effect on functioning, mediated by negative symptoms. However, this approach is 
concerning given that measures of negative symptoms, namely avolition subdomains, overlap 
with functional measures. As such, we cannot ascertain whether lack of motivation is associated 
with poor functioning when both variables are measuring the same overt behavioral markers.  
 
To address these limitations, further study on the role that avolition plays in the development of 
functional outcomes using multivariable regression models that include a full range of clinical 
and psychosocial confounding factors, without overlapping negative symptom measures, is 
warranted.  
 
2.8 Study Rationale and Research Questions 
With growing interest in understanding the factors that affect functioning and achieving 
functional remission in people with psychosis, the identification of modifiable treatment targets 
to improve functionality is important. Given that avolition has been found to be highly correlated 
with functioning, the nature of this relationship to functioning needs to be further studied. To 
better inform the observed relationship between avolition and impaired functioning and address 
past study limitations, there is a need for more nuanced research on the internal driving factors of 
motivation and their relationship to functional outcomes. Therefore, the aim of this thesis was to 
examine the direct effects of internal drivers of motivation and functioning in a cross-sectional 
sample of people with psychotic disorders, in order to address the following research questions:  
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1. Is there a relationship between intrinsic, psychological drivers of motivation and 
functional outcomes? 
 
2. Is there a difference in the relationship between these motivational drivers and specific 
functional domains? 
 
2.9 Thesis Objectives and Hypotheses 
2.9.1 Objective 1 
Findings from studies assessing the relationship between clinical variables and functional 
outcomes in people with psychotic disorders have consistently shown a significant relationship 
between negative symptoms, namely avolition, and functioning. However, due to methodological 
and validity issues around the assessment of functional outcomes and avolition, findings are 
questionable and require the assessment of more intrinsic motivational factors in regard to 
functioning. Given the need for (a) a better understanding of how to address negative symptoms, 
(b) more intrinsic measures of motivation that may lead to avolition, and (c) treatment targets to 
improve functional recovery, we sought to examine and compare the associations between 
internal drivers of motivation (self-efficacy, anticipatory pleasure capacity, and defeatist 
performance beliefs) and overall functioning among people with a psychotic disorder, without 
the confounding effects of avolition and negative symptoms among people with psychotic 
disorders.  
 
Hypothesis for Objective 1 
We hypothesized that there would be a significant association between each identified internal 
driver of motivation and overall functioning. Specifically, we hypothesized that people with 
higher self-efficacy, high anticipatory pleasure capacity, and lower defeatist performance beliefs 
would experience better overall functioning.  
 
2.9.2 Objective 2 
To our knowledge, no study to date has examined the role of multiple motivational drivers on 
specific domains of functioning among people with psychosis. Given that functional outcomes 
can be divided into separate domains of functioning, we sought to assess the relationships 
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between the identified internal drivers of motivation and specific domains of functioning, 
specifically working productivity, independent living and self-care, immediate social networks, 
and extended social networks in a sample of people with a primary psychotic disorder, adjusting 
for demographic and clinical covariates. 
 
Hypothesis for Objective 2 
Given the exploratory nature of this objective, we did not have any set hypotheses in regard to 
the relationships between each driver of motivation and each functional domain. However, we 
expected that there would be observable differences between each driver of motivation within 
each functional domain, and between domains and hypothesized that drivers of motivation would 
work independently of each other in regard to their impact on functional sub-domains. 
 
 
  
  
29 
 
Chapter 3 
3 Methods 
3.1 Data Source 
This cross-sectional, descriptive study uses data from a shared data repository composed of two 
studies that were conducted by an early psychosis intervention (EPI) program, known as the 
Prevention and Early Intervention Program for Psychoses (PEPP). Established in 1997, PEPP is 
an outpatient mental health treatment programme located at Victoria Hospital, London Health 
Sciences Centre in London, Ontario, Canada. PEPP uses a comprehensive approach to treatment 
of non-affective psychotic disorders with intensive medical and psychosocial management 14,120. 
The PEPP shared data repository consists of (1) a prospective cohort study assessing 10-year 
outcomes of individuals who were clients of PEPP; and (2) a cross-sectional study assessing the 
magnitude, nature and determinants of negative symptoms of current clients of PEPP. Both 
studies received ethics approval from Western University’s Health Sciences Research Ethics 
Board (Appendix A). No additional ethics approval was necessary for the purposes of this thesis 
as the objectives and methods fell within the scope of the approved protocols. 
 
3.2 Study Setting 
PEPP is an integrated clinical and research-based program developed for providing improved 
care while simultaneously collecting data on patient outcomes, in order to develop an evidence 
base for improving service delivery and our understanding of psychotic disorders and 
determinants of outcome 121. PEPP is geared towards the treatment of non-affective psychotic 
disorder. At the time of data collection for these studies, PEPP employed strategies to reduce 
delays in receiving assessment and treatment by using an open referral policy, with a response 
time for assessment occurring rapidly after initial referral 120. Following referral, patients are 
screened by a PEPP clinician for symptoms of psychosis. If presenting with such, patients then 
undergo a more comprehensive diagnostic assessment by a PEPP psychiatrist. Patients with a 
primary psychotic disorder who are between the ages of 16 to 40 years (prior to 2014, patients up 
to 50 years of age were eligible), live within the defined catchment area, and have not received 
antipsychotic treatment for a period greater than one month are considered eligible and are 
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accepted into the program once a consent for assessment and treatment is given 120. Further 
information on PEPP services can be found within Appendix D. 
 
3.3 Study Procedure  
Data from two studies, titled the “Assessment of 10 Year Outcomes for Clients of the Prevention 
and Early Intervention Program for Psychoses (PEPP)” and the “Understanding Negative 
Symptoms in Patients of an Early Intervention Program for Psychotic Disorders”, are included 
within our data set with the former being referred to as “the 10-year patient outcome study” and 
the latter being referred to as “the negative symptom study”.  
 
The 10-year outcome study collected data from patients at baseline, one-year follow-up, five-
year follow-up and again at 10-year follow-up. This thesis focuses on follow-up assessments 
conducted at 10 years, as well as assessments conducted in regard to the negative symptom 
study. 
 
Both studies had assessment periods conducted at similar time points (2014-2015) and with 
overlapping objectives, namely the assessment of symptomology among individuals with 
psychosis, the identification of potential covariates, the evaluation of functioning, quality of life 
and other measures of recovery, and a more detailed assessment of negative symptoms and 
correlated/predictors of variation in these symptoms. Due to this similarity across study 
objectives and procedures, we were able to combine the PEPP data sets for our analyses, for a 
total combined dataset of 105 participants; 69 from the 10-year outcome study and 36 from the 
negative symptom study.  
 
Participants were provided with a letter of information regarding the nature and purpose of the 
study as well as a letter of consent in which they agreed to participate in assessment interviews, 
which were scheduled at a time convenient for the participant. Assessment involved the 
completion of a battery of clinical and non-clinical outcome measures. Completion of the 
assessments were split between two days, separated by one to two weeks. A random number 
system was used to determine which measures would be administered to the participant at each 
meeting. Written informed consent was obtained from each participant at his/her first assessment 
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interview. Demographic information was recorded by means of a demographic questionnaire and 
outcome measures were administered using a semi-structured interview format. All clinical 
measures were administered by a clinical psychologist or psychiatrist, whereas non-clinical 
measures were administered by the research coordinator who was trained and supervised by the 
clinical psychologist.  
 
As assessments were completed, the interviewer paid attention to each participant’s demeanor 
and energy level. In instances where these factors were diminished, participants were encouraged 
to take a break and complete the rest of the assessments at a subsequent session one to two weeks 
later.  
 
3.4 Data Set 
Access to the PEPP shared data repository was obtained from the principal investigator of the 
source studies. The principal investigator was tasked with extracting the requested subset of 
variables from the PEPP shared data repository and creating the data set, which was then 
transferred for use in the current analyses. 
 
Upon receipt of the data set, SPSS was used to convert the database from SPSS format to SAS 
format (.sav to .sas7bdat). SAS version 9.4 122 was then used to ‘clean’ the data. This step 
included assessing the distribution of all variables, checking for potential outliers, and re-labeling 
and re-coding of variables.  
 
3.5 Variables and Measures 
3.5.1 Exposure Variables 
Self-Efficacy 
Self-efficacy is defined as the confidence one has in their ability to perform a behavior or 
specific task 123. To assess self-efficacy, the Generalized Self-Efficacy scale (GSE) was used123. 
The GSE is a self-report rating scale consisting of ten items scored using a 4-point Likert scale 
ranging from one (Not at all True) to four (Very True). Although self-efficacy is understood to 
be domain specific, meaning that one can have more or less firm self-beliefs in different domains 
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or situations, the GSE assesses a generalized sense of self-efficacy, which refers to overall 
confidence in one’s ability to cope with a wide range of novel and/or demanding tasks 123. This 
concept of generalized self-efficacy consists of a two-part cognitive set composed of a sense of 
successful agency and pathways 123. The agency component reflects a goal-directed 
determination, and the pathways component reflects an ability to plan ways to meet said goals.   
 
The GSE has been used in previous research as a tool to assess self-efficacy and dysfunctional 
beliefs about one’s self, and has demonstrated high internal consistency among 127 outpatients 
diagnosed with schizophrenia with an ICC value of 0.9 106. It also demonstrated a high test-retest 
reliability with ICC values ranging from 0.69 to 0.8 among multiple samples of university 
students 123,124. Along with being parsimonious and reliable, the scale has demonstrated both 
convergent and discriminant validity.  
 
For the purpose of this thesis, we used the GSE as a measure of one’s overall sense of self-
efficacy. Total scores on this measure range from 10 to 40, with higher scores indicative of a 
greater sense of self-efficacy. All analyses used the GSE as a continuous variable.  
 
Anticipatory Pleasure Capacity 
Anticipatory pleasure is defined as the ability to feel pleasure in regard to future activities, 
leading to one having the experience of ‘wanting’ 116. To assess anticipatory pleasure, the 
Temporal Experience of Pleasure scale (TEPS) was administered116. The TEPS is an 18 item 
self-report measure that assesses two domains of pleasure, being anticipatory pleasure (10 
items; e.g. “When I hear about a new movie starring my favourite actor, I can’t wait to see it.”) 
and consummatory pleasure (8 items; e.g. “I enjoy taking a deep breath of fresh air when I 
walk outside.”).  Anticipatory pleasure has been shown to be more closely linked to motivation 
and goal-directed behavior, whereas consummatory pleasure has been shown to be closely linked 
to satiation 116.Therefore, items written to relate to anticipatory pleasure capacities reflect 
pleasure experiences in anticipation of a positive and/or pleasurable stimulus, whereas items 
written to relate to consummatory pleasure reflect in-the-moment pleasure in response to a 
stimulus. Items were written in regard to both specific and general situations that involved all 
five sensory modalities and that focused on the domain of physical pleasure. Items are rated on a 
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6-point Likert scale ranging from one (Very False for Me) to six (Very True for Me). Items 
related to anticipatory pleasure were used to create a total score for one’s level of anticipatory 
pleasure capacity (Appendix E). Total scores on this subscale range from 10 to 60, with higher 
scores indicative of a higher capacity for anticipatory pleasure.  
 
The TEPS has demonstrated good internal consistency for the total scale as well as both 
subscales for anticipatory and consummatory pleasure, with a Cronbach’s a of 0.87, 0.71 and 
.78, respectively, among a sample of 86 persons diagnosed with schizophrenia 125. The test-retest 
reliability of the scale and subscales have all been found to be high (r= 0.75; p<0.001) 116. When 
tested against scales on pleasure, the TEPS was found to be related but clearly distinguishable 
from measures of personality, motivation, and pleasure constructs 116. 
 
As previously stated, individuals with psychotic disorders such as schizophrenia have been found 
to have intact consummatory pleasure capacities, with deficits being observed within the 
anticipatory pleasure domain. These deficits in anticipatory pleasure have been linked to both 
negative symptoms and functional outcomes. For the purpose of this thesis, the anticipatory 
pleasure subscale score was used as a measure of anticipatory pleasure capacity and was used as 
a continuous variable in all analyses. 
 
Defeatist Beliefs 
Defeatist beliefs are defined as overgeneralized negative thoughts about one’s ability to 
successfully perform goal directed behavior 97. To assess defeatist beliefs, the Defeatist 
Performance Beliefs scale (DPB) was used97. The DPB, a subscale of the Dysfunctional 
Attitudes Scale, is a 15-item self-report measure that includes statements concerning one’s 
ability to perform tasks and the likelihood of their success (e.g. “If I do not do as well as other 
people, it means I am an inferior human being.”) Items are scored using a 7-point Likert scale 
ranging from one (Totally Agree) to seven (Totally Disagree).  
 
The DPB has been used in previous studies as a measure of defeatist beliefs in patients with 
psychosis 91,96-98 and has demonstrated high internal consistency, with Cronbach’s a of 0.85 96,98.  
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For the purpose of this thesis, the total score on the DPB was used as a measure of defeatist 
performance beliefs. Total scores on this unidimensional measure range from 15 to 105, with 
lower scores being indicative of a high degree of defeatist performance beliefs. All analyses 
conducted for this thesis used the DPB as a continuous variable.  
 
3.5.2 Outcome Variable 
Functioning  
Functioning was assessed using the Role Functioning Scale (RFS)79, consisting of four single 
rating scales that are used to evaluate levels of functioning in specific subdomains of everyday 
life: (1) Working Productivity; (2) Independent Living and Self-Care; (3) Immediate Social 
Network Relationships; and (4) Extended Social Network Relationships. The RFS is scored 
using a seven-point Likert scale ranging from one (Minimal Level of Role Functioning) to seven 
(Optimal Level of Role Functioning), with each of the seven points on the scales accompanied 
by a behaviorally defined description (e.g. Working Productivity, “Productivity severely limited; 
often unable to work or adapt to school or homemaking; virtually no skills or attempts to be 
productive”.) The total of the four role scores represents a Global Role Functioning Index, with 
total scores ranging from 4 to 28. The RFS is administered via a standardized interview, with the 
patient being evaluated based on a specified time period, such as the previous week. 
 
The RFS has demonstrated its ability to discriminate accurately between psychiatric and non-
psychiatric patients of varying functional capacity and shows good inter-item (a=0.92), test-
retest (r=0.85 to 0.92) and inter-rater reliability (t=0.64 to 0.820) 79. 
 
For the purpose of this thesis, we used the RFS Global Index score as an overall assessment of 
functioning as well as the subdomain scores for functional capacity in specified areas of 
everyday life with higher scores being indicative of better functional outcome. The global index 
is a composite measure of the four Likert subscales, with each subscale being a 7-point Likert 
scale, and therefore measured ordinally. However, studies and reviews on the use of Likert data 
with parametric testing methods have shown that with ordinal measures that have five or more 
categories, the data can be treated as continuous 126-129. It has also been demonstrated that 
parametric testing methods can be used, which are generally more robust than non-parametric 
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testing methods, especially when there is an adequate sample size and if normality is observed 
within the data 128,129. Therefore, for the purposes of consistency with our first objective, we 
chose to treat the sub-domain scores as continuous for our main analyses.  
 
3.5.3 Potential Covariates 
For our main analyses, we controlled for 11 variables that were identified as possible covariates, 
and were examined in previous studies, through our literature review with information pertaining 
to the relationship between these variables and our exposure and outcome variables presented 
below. We were unable to control for four additional variables identified as potential covariates 
due to their exclusion from assessments within the negative symptom study, specifically age of 
onset, mode of onset, duration of untreated psychosis and premorbid adjustment. Because these 
variables were assessed for the 10-year outcome study, we conducted sensitivity analyses on the 
subset of data from the 10-year outcome study, including these variables and the other identified 
covariates. Information pertaining to these four additional variables and the measures used for 
assessment can be found in Appendix F. 
 
Age 
Age, measured in years, was assessed at baseline using the demographics questionnaire and was 
treated as a continuous variable in our main analyses. 
 
Gender 
Gender was assessed at baseline using the demographics questionnaire and was treated as a 
dichotomous variable, with possible response items being either Male or Female. In comparison 
to males, females have been associated with a higher level of functioning 20,130-132. Furthermore, 
females have been associated with greater premorbid adjustment, a shorter duration of untreated 
psychosis, and a higher level of education, in comparison to males 130. 
 
Education 
Education, measured in years, was assessed using the demographics questionnaire. Higher 
education has been shown to be associated with greater functional outcomes 20,47,132. Data on 
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years of education was used as a proxy indicator of socio-economic status and treated as a 
continuous variable for all analyses.  
 
Length of Treatment 
Length of treatment was defined as the length of time, in years, from the date of admission into 
PEPP to the date of assessment. These dates were obtained from demographic questionnaires. 
Given that our data set contained participants from two separate studies, participants’ length of 
treatment varies depending on the study they participated in. In our analyses, length of treatment 
was used as a continuous variable.  
 
Perceived Social Support 
Social support was assessed using the Interpersonal Support Evaluation List (ISEL)133, a 40-item 
self-report measure of perceived social support in which items are dichotomously scored 
(Probably True vs. Probably False). The ISEL calculates total scores as well as subdomain scores 
assessing four domains of social support including appraisal (10 items; e.g. “There are several 
people that I trust to help solve my problems.”), tangible (10 items; e.g. “If I needed help fixing 
an appliance or repairing my car, there is someone who would help me.”), self-esteem (10 items; 
e.g. “Most of my friends are more interesting than I am.”) and belonging (10 items; e.g. “When I 
feel lonely, there are several people that I can talk to.”). Total scores for each subdomain range 
from 0 to 10, with higher scores indicative of higher perceived social support within that specific 
domain. 
 
The ISEL has been shown to have a high degree of test-retest reliability after a four-month 
period (r=0.83) as well as internal consistency (a=0.93), among a sample of 59 individuals with 
Bipolar I disorder 134. Social support has been found to be associated with improved functional 
outcomes in individuals with schizophrenia 135-137, with the presence of a support system during 
early stages of illness predicting better functioning 136. 
 
For the purpose of these analyses, the total perceived social support score was computed using 
the total score from each domain of the ISEL, with the total score used as a continuous variable 
for all analyses.  
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Positive Symptoms 
Positive symptoms were assessed using the Scale for the Assessment of Positive Symptoms 
(SAPS)138. The SAPS is a 34 item, six-point Likert scale with individual item scores ranging 
from zero (Absent) to five (Severe). The SAPS provides both a total score as well as subdomain 
scores pertaining to four positive symptoms, including: (1) Hallucinations (7 items; e.g., 
Auditory Hallucinations, “The patient reports voices, noises, or other sounds that no one else 
hears.”); (2) Delusions (13 items; e.g. Persecutory Delusions, “The patient believes he is being 
conspired against or persecuted in some way.”); (3) Bizarre Behavior (5 items; e.g. Clothing 
and Appearance, “The patient dresses in an unusual manner or does other strange things to alter 
his appearance.”);  and (4) Positive Formal Thought Disorder (9 items; e.g. Derailment, “A 
pattern of speech in which ideas slip off track onto ideas obliquely related or unrelated.”). 
 
As a reference point, all items are answered using the time frame of the past month. Total scores 
range from 0 to 150, with higher scores indicative of a greater severity of positive symptoms. 
Subdomain ratings range from 0 to 65, depending on the subdomain, with higher scores 
indicative of a greater severity of that specific positive symptom. 
 
The SAPS has been used frequently in both research and clinical-based settings and has 
demonstrated high inter-rater reliability (ICC=0.84) for total summary scores, as well as 
moderate to high inter-rater reliability for ratings of each subdomain: hallucinations (ICC=0.91), 
delusions (ICC=0.86), bizarre behavior (ICC=0.50), and positive formal thought disorder 
(ICC=0.75) 139. Higher positive symptom severity is associated with, poorer social support140, a 
greater level of amotivation 141, and poorer functional outcomes in individuals with psychotic 
disorders 20,47,72,131,142. 
 
For the purpose of this thesis the total score on the SAPS was used as a measure of positive 
symptom severity and was computed by summing the total scores on each subdomain of the 
SAPS. This measure was used as a continuous variable for all analyses. 
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Negative Symptoms 
Negative symptoms were assessed using the Scale for the Assessment of Negative Symptoms 
(SANS)31. The SANS is a 25 item, 6-point Likert scale with individual item scores ranging from 
zero (Absent) to five (Severe). The SANS provides both a total score as well as subdomain 
scores pertaining to five negative symptoms, being: (1) Affective Flattening or Blunting (8 
items; e.g., Unchanged Facial Expression, “The patient’s face appears wooden -changes less than 
expected as emotional content of discourse changes.”), (2) Alogia (5 items; e.g. Poverty of 
Speech, “The patient’s replies to questions are restricted in amount, tend to be brief, concrete, 
unelaborated.”), (3) Avolition-Apathy (4 items; e.g. Grooming and Hygiene, “The patient’s 
clothes may be sloppy or soiled, and he may have greasy hair, body odour, etc.”), (4) 
Anhedonia-Asociality (5 items; e.g. Recreational Interests and Activities, “The patient may 
have few or no interests. Both the quality and the quantity of interests should be taken into 
account.”) and (5) Attention (3 items; e.g. Social Inattentiveness, “The patient appears 
uninvolved or unengaged. He may seem “spacey”.”). 
 
As a reference point, all items are answered using the time frame of the past month 143. Total 
scores range from 0 to 100, with higher scores being indicative of a higher severity of negative 
symptoms. Subdomain ratings, or global ratings, range from 0 to 25, with higher scores being 
indicative of a higher severity of that specific negative symptom. 
 
The SANS has demonstrated moderate to high internal consistencies for the five negative 
symptom domains: affective flattening (α=0.81), alogia (α=0.81), attentional impairment 
(α=0.84), avolition-apathy (α=0.80), and anhedonia-asociality (α=0.63) 53. 
 
As discussed in chapter two, the SANS total score and subdomain scores demonstrated a high 
degree of overlap between negative symptoms and functioning, confirmed in the study dataset 
using Pearson correlation coefficients; therefore, SANS scores were excluded from the main 
analyses. In the secondary correlation analyses, the SANS total score and subdomain scores were 
used as a measure of negative symptoms and were treated as continuous variables. 
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Depression and Anxiety 
Depressive and anxiety symptoms were assessed using the Profile of Mood States-Short Form 
Questionnaire (POMS-SF)144. The POMS-SF is a measure of psychological distress consisting of 
37 adjectives (e.g. “Tense”), to which responders are asked to describe how often they 
experience the feeling or mood over the course of the past two to three months 144. Responses are 
recorded using a five-point Likert scale, with responses ranging from zero (Not at all) to four 
(Extremely). Scoring of the POMS-SF yields an overall total mood disturbance score, as well as 
scores for six subscales: Fatigue-Inertia (5 items; e.g. “Worn Out”), Vigor-Activity (6 items; 
e.g. “Lively”), Tension-Anxiety (6 items; e.g. “Tense”), Depression-Dejection (8 items; e.g. 
“Unhappy”), Anger-Hostility (7 items; e.g. “Grouchy”), and Confusion-Bewilderment (5 
items; e.g. “Forgetful”). 
 
Total mood disturbance scores range from 0 to 148, and subdomain total scores range as follows: 
0 to 20 for Fatigue-Inertia, 0 to 24 for Vigor-Activity, 0 to 24 for Tension-Anxiety, 0 to 32 for 
Depression-Dejection, 0 to 28 for Anger-Hostility and 0 to 20 for Confusion-Bewilderment. 
Higher scores on the total mood disturbance scale are indicative of greater mood disturbance, 
and higher scores on each subdomain reflect greater mood disturbance for each specific domain. 
 
Across multiple samples, the POMS-SF demonstrated high internal consistency (α= 0.76 to 0.95) 
with internal consistency estimates being generally similar to or exceeding the original POMS 
measure 144. As well, there was a high degree of reliability across samples for each mood state (r 
=0.81-0.95) 144. 
 
In individuals with psychosis, both symptoms of depression and anxiety have been found to be 
correlated with amotivation 145 and poorer functional outcomes 47,72,146,147. Additionally, the 
experience of anxiety has been found to be associated with greater positive symptom severity 
and depressive symptoms 147. For the purpose of this thesis, only the Depression-Dejection and 
Tension-Anxiety subdomains were used for our analyses, with these variables being treated as 
continuous measures. 
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Drug Use 
Drug use was assessed using the Drug Abuse Screening Test (DAST-20)148. The DAST is a 20-
item self-report measure of drug use within the last three months, with drug use defined as any 
non-medical use of drugs, not including alcohol (e.g. “In the last 3 months, have you used drugs 
other than those required for medical reasons?”). Items are scored dichotomously, either Yes or 
No, with a score of one for every Yes response, with three items reverse coded. If the responses 
for question 1 (i.e. “Have you used drugs other than those required for medical reason?”) and 2 
(i.e. “Have you abused prescription drugs?”) were No, then the remaining items were not to be 
completed. Total scores on the DAST-20 range from 0 to 20, with higher scores indicative of 
greater drug use. Comorbid substance use is considered a major obstacle to recovery amongst 
individuals with psychotic disorders 149, with comorbid substance use being associated with an 
earlier age of onset, younger age, male gender lower educational attainment and poorer outcomes 
such as greater symptom severity and employment and housing instability 149,150. 
 
A cut-off score of 6 or above for the DAST-20 has been recommended for detection of substance 
abuse or dependence among 97 psychiatric patients with an Axis 1 mental disorder other than 
substance use or dependence (sensitivity, 89-84% and specificity, 68-83%) 151,152. Psychometric 
studies on the DAST-20 have shown the DAST-20 to have a high degree of internal consistency 
(α =0.74-0.95), and test-retest reliability (ICC=0.71) among a sample of 97 psychiatric patients 
with an Axis 1 mental disorder 151. 
 
Although the DAST-20 has a recommended cut-off score (i.e. 6 or above), we chose to group 
scores into three categories due to the majority of participants scoring 0 on the DAST-20. 
Therefore, DAST-20 was treated as an ordinal variable with responses falling into one of three 
possible categories: no drug use (i.e. DAST-20 score of 0), drug use below the cut-off score (i.e. 
DAST-20 scores of 1 to 5) or detected drug abuse (i.e. DAST-20 score of 6 or above). 
 
Alcohol Use 
Alcohol use severity was assessed using the Alcohol Use Disorders Identification Test 
(AUDIT)153. The AUDIT is a 10-item, self-report measure of alcohol use with the reference 
point being within the past three months (e.g. “During the last 3 months, how often did you have 
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a drink containing alcohol?”). All items are scored on a five-point Likert scale with scores 
ranging from zero to four. However, if the response to item one (“During the last three months, 
how often did you have a drink containing alcohol?”) is zero, then the remaining nine items are 
not to be completed. Total scores on this measure can range from 0 to 40, with higher scores 
indicative of a greater severity of alcohol use. As with drug use, excessive alcohol use is 
associated with greater symptom severity and a greater risk of mental illness comorbidities 
149,150,154, with individuals diagnosed with a substance use disorder being more likely to have 
depression 154. 
 
The AUDIT has shown high internal consistency when used in a sample of 80 individuals with 
schizophrenia (α =0.81) 155. As well, an AUDIT cut-off score of eight was shown to have a 
sensitivity of 87% and specificity of 90% for detecting alcohol disorders diagnosed by the 
Composite International Diagnostic Interview among psychiatric patients (n=71) with a 
diagnosis of schizophrenia 155,156. 
 
For the purpose of this thesis, AUDIT scores were treated as categorical, with responses being 
grouped into one of three possible categories: no alcohol use (i.e. AUDIT score of 0), use below 
the cut-off score (i.e. AUDIT score of 1 to 7), and alcohol abuse (i.e. AUDIT score of 8 or 
above). 
 
Medication Adherence 
Medication adherence refers to the use of either first or second-generation antipsychotic 
medication, and was assessed using the Adherence to Medication Scale, which is a single-item 
question pertaining to both the past month and year (i.e. “Based on all available information, 
approximately what percentage of time has the patient been taking medication as prescribed?”). 
For the purpose of this thesis, we chose to use data pertaining to the past month. Development of 
this question was based on results from studies assessing multiple measures of antipsychotic 
medication adherence in patients with a first episode of psychosis 157. In individuals with 
schizophrenia, non-adherence to antipsychotic medication has been associated with a greater 
severity of positive symptoms 137, poorer functional outcomes, alcohol dependence and 
substance use disorders 158 and an increased risk of psychiatric hospitalization 158,159. 
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The scale is rated by the interviewer based on information obtained from the primary clinician, 
case manager, family members, and the patient themselves 157. The estimate is rated using a 4-
point scale: 1 (0-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). Where there was 
disagreement between sources on adherence, each case was discussed until a consensus was 
reached, however the primary clinician’s estimate on medication adherence carries the most 
weight in the decision. 
 
In a comparison study assessing the use of multiple measures of adherence to antipsychotic 
medication with a sample of 81 first-episode psychosis patients, Cassidy and colleagues found 
that patient reports, pill counts, and clinical reports had good agreement (ICC=0.84), and that all 
the measures used were highly correlated to consensus adherence scores (r=0.86 to 0.98)157. 
 
Due to a lack of variability in scores, we chose to treat the variable as dichotomous instead of 
categorical. Participant scores were grouped into one of two categories; either less than or equal 
to 75% medication adherence (i.e. no medication use to a score of 3) or greater than 75% 
medication adherence (i.e. score of 4). 
 
3.6 Missing Data 
To determine the extent of missing data within our sample, we first examined (1) the total 
number of cases (i.e. participants) with missing observations; (2) the total number of variables 
with missing observations; and (3) the number of missing observations for the exposure, 
outcome, and potential covariates. Our findings from these analyses are presented in Table 3.1. 
 
Once the extent of missing data had been determined, we examined the pattern of modality of the 
missing data. In order to do this, we had to first distinguish between two patterns of missing data 
(1) Monotone; and (2) Arbitrary 160,161. A monotone missing data pattern exists if there is a clear, 
observable pattern among the variables that are missing. If there is no evident pattern observed, 
then the missing data pattern is said to be arbitrary. 
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Table 3.1: Missing Data within the Study Sample 
 
Missing Data Assessment N (Percentage Missing) 
Total number of cases with missing data 50 (47.6%) 
Total number of variables with missing data 79 (37.3%) 
Exposure Variables  
Generalized Self Efficacy Score 1 (0.9%) 
Temporal Experience of Pleasure- Anticipatory Score 2 (1.9%) 
Defeatist Performance Beliefs Score 5 (4.8%) 
Outcome Variable  
Role Functioning Scale 0 (0.0%) 
Work Subscale 0 (0.0%) 
Independent Living Subscale 0 (0.0%) 
Immediate Social Network Subscale 0 (0.0%) 
Extended Social Network Subscale 0 (0.0%) 
Potential Covariate Variables  
Age 1 (0.9%) 
Gender 0 (0.0%) 
Education (years) 10 (9.5%) 
Age of Onset * 39 (37.14%) 
Mode of Onset * 38 (36.19%) 
Duration of Untreated Psychosis (weeks) * 38 (36.19%) 
Length of Treatment 1 (0.9%) 
Premorbid Adjustment Score * 46 (43.81%) 
Perceived Social Support Score 2 (1.9%) 
Depressive Symptoms 2 (1.9%) 
Anxiety Symptoms 2 (1.9%) 
Positive Symptoms 0 (0.0%) 
Negative Symptoms 0 (0.0%) 
Drug Use 1 (0.9%) 
Alcohol Use 1 (0.9%) 
Medication Adherence 5 (4.8%) 
Note: n= Count; Case = Participant; Total number of observations = 105; Total number of variables=221; 
* Variables missing large percentages of data were excluded from main analyses 
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Once the pattern of modality had been determined, we then determined the mechanism of 
missing data, of which there are three possible forms: (1) Missing completely at random 
(MCAR); (2) Missing at random (MAR); and (3) Not missing at random (NMAR) 160,162. MCAR 
refers to the case where the probability that a value for a particular variable is missing is not 
dependent on other measured variables included in the data set and is not related to the value of 
the missing variable. MAR refers to instances where the probability of a missing data value for a 
specific variable is related to other measured variables in the data set, however it is unrelated to 
the value of the missing variable. Finally, NMAR refers to instances where the probability of a 
missing data value for a variable is dependent on the value of the missing variable 160,163. From 
assessing the dataset, we determined that the pattern of missing data was arbitrary, and that the 
mechanism of the missing data was MAR for all data. 
 
When determining the method to handle missing data, we took into account the pattern, 
mechanism, and characteristics of the included variables along with our intention to retain the 
entire sample (n=105). We therefore decided to use multiple imputation to handle the missing 
data present in our data set. Multiple imputation is a method of accounting for missing data 
whereby a missing value is imputed multiple times using a set of plausible values sampled from 
an imputation model 161. 
 
Multiple imputation involves three stages: (1) Imputing, (2) Analyzing, and (3) Pooling. The 
imputing stage is the first step of the procedure where the missing values are imputed m times to 
create m complete data set copies. These imputed values are sampled from their predictive 
distribution based on the observed data. The next step is to analyze the m completed data sets to 
obtain m sets of parameter estimates and corresponding standard errors for the missing values. 
These estimates will differ for the m imputed data sets because of the variation introduced during 
the imputation phase and must be averaged together to give an overall estimate. Therefore, the 
final stage yields parameter estimates, standard errors, and confidence intervals for each of the m 
completed data sets that are pooled together to create one overall estimate 160.  
 
To use the multiple imputation method, we had to decide whether we wanted to construct our 
imputation model using the multivariate normal method (MVN) or the fully conditional 
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specification (FCS) method 161. The multivariate normal method assumes that all variables 
included in the imputation model jointly follow a multivariate normal distribution. Therefore, the 
imputation stage uses a Bayesian approach to obtain the imputed values from this multivariate 
normal distribution, which allows for uncertainty in the estimated model parameters 161. The 
fully conditional specification method, also known as the chained equations method, has a more 
flexible approach to multiple imputation in that it does not rely on the assumption of multivariate 
normality. Conditional distributions are specified for each variable with missing values, and 
imputations are generated by estimating each of these conditional distributions in turn using 
observed cases for the variable being considered and imputed values for the other variables at 
that iteration, thereby imputing the missing values 161. This again allows for uncertainty in the 
model parameters. Given that our dataset includes different types of variables (i.e. continuous, 
binary, and categorical) we decided to use the FCS method due to its ability to model each 
variable using its own distribution, and therefore our regression models can be tailored 
appropriately with logistic regression being used for binary variables and linear regression for 
continuous variables. In terms of the number of imputations (m), we chose 50 imputations 
(m=50) based on the rule of thumb that the number of imputations should be similar to the 
percentage of incomplete cases within the data set 164,165. 
 
3.7 Statistical Analyses 
All statistical analyses were conducted using SAS version 9.4 122, with all hypothesis testing 
using a type 1 error rate set at alpha=0.05, two-tailed.  
 
3.7.1 Descriptive Statistics 
Descriptive statistics were summarized for all included participants. Categorical variables were 
analyzed using counts and percentages, and continuous variables were analyzed using means and 
standard deviations.  
 
3.7.2 Multicollinearity 
Given the inclusion of multiple exposure variables and their relation to the construct of 
motivation, we assessed for multicollinearity. Multicollinearity describes the situation when one 
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variable in a regression model can be linearly predicted from the other variables. It occurs when 
two or more variables that are highly correlated with each other are included in the same 
regression model and used together to predict the outcome variable 166,167. Issues arise with 
multicollinearity due to its impact on effect estimation, with regression coefficients being 
imprecisely measured and standard errors being high resulting in wide confidence intervals. 
Taken together, these issues make it difficult to reject the null hypothesis 166,167. To assess for the 
presence of a high degree of multicollinearity, we used variance inflation factors with the 
selected cut-off point of VIF ≥5. The variables were below the selected cut off value, which 
indicates a low degree of multicollinearity in our regression models. Although no standard cut-
off value for VIF exists, various cut-off values have been used in previous research, ranging 
from scores of five to ten 168,169.  
 
3.7.3 Correlation Assessments  
To assess the degree of correlation between study variables, we conducted a series of Pearson 
correlation matrices to examine the associations between drivers of motivation, avolition, and 
functional outcomes.  
 
3.7.4 Analysis: Objective 1 
Our first objective was to determine the relationship between indicators of motivation and 
functional outcome among people with primary psychotic disorders. We conducted a series of 
simple linear regression models to assess the relationship between each exposure and covariate 
variable and the outcome variable global functioning. We then constructed a multivariable linear 
regression model to assess the relationship between the identified indicators of motivation (self-
efficacy, defeatist performance beliefs, and anticipatory pleasure capacity) and the outcome 
variable of global functioning, adjusting for potential covariates including age, gender, 
education, length of treatment, social support, positive symptoms, depression, anxiety, drug use, 
alcohol use and medication adherence. We hypothesized that there would be a positive 
association between self-efficacy and functional outcome, a positive association between 
anticipatory pleasure capacity and global function, and a negative association between defeatist 
performance beliefs and global function, adjusting for potential covariates.  
 
  
47 
 
3.7.5 Analysis: Objective 2 
Our second objective was to explore the relationship between these indicators of motivation and 
specific subdomains of functioning. First, we conducted a series of simple linear regression 
models to assess the relationship between all four subdomains of functioning and each exposure 
variable and potential covariates factor. We then constructed four multivariable linear regression 
models to assess the relationship between the identified indicators of motivation (self-efficacy, 
defeatist performance beliefs, and anticipatory pleasure capacity) and the sub-domains of the 
RFS: (i) work, (ii) independent living, (iii) immediate social network, and (iv) extended social 
network, adjusting for covariate factors. Each model included the three identified indicators of 
motivation as the exposure variables, one of the four subdomains of functioning as the outcome 
variable, and the potential covariate variables listed above.  
 
3.7.6 Sensitivity Analyses 
We conducted sensitivity analyses to assess the robustness of our findings by repeating 
objectives one and two using data from the 10-year outcome study, which contains information 
on additional covariate factors not available in the full dataset, specifically age of onset, mode of 
onset, duration of untreated psychosis and premorbid adjustment. Using imputed data (n=69) for 
participants of the 10-year outcome study that included additional information on covariate 
variables that we were unable to include in our main analyses, we repeated our analyses using 
these four additional covariates with the variable age being replaced with age of onset. As an 
additional sensitivity analysis, given that the RFS is a Likert-based scale, we repeated our 
objective one and two analyses using an ordinal logistic regression models treating the outcome 
variable as categorical in order to test the robustness of our findings to these methodological 
decisions. 
 
  
48 
 
Chapter 4 
4 Results 
In this chapter, we present descriptive statistics for our study sample in Section 4.1. In Section 
4.2, findings from our analyses of the correlation between negative symptoms, avolition, and 
functional outcomes are reported. In Section 4.3, the results from our series of simple and 
multivariable linear regression analyses assessing the association between motivational drivers 
and global functioning, conducted for objective 1, are presented. This is followed by the results 
of our series of simple and multivariable linear regression analyses for each subdomain of 
functioning conducted for objective 2. In Section 4.5, findings from our sensitivity analyses are 
presented.   
 
4.1 Descriptive Statistics 
Socio-demographic and clinical characteristic of our study sample are summarized in Table 4.1. 
Our sample (n=105) consisted of a higher proportion of males (72%) than females (28%), with a 
mean age of 34.2 years (SD=9.9), ranging from 19 to 60 years. The majority of participants were 
European American (85%), single (74%) and had a diagnosis of a primary psychotic disorder 
(94.3%). Participants were found to be fairly evenly split between being employed (48.6%) and 
unemployed (45.7%), with a few participants classified as students (2.9%).  The majority of 
participants were living with others (68%) and earning an annual income of $29,999 or less 
(87%). With respect to the exposure variables within our study sample, participants had a mean 
generalized self-efficacy score of 30.9 (SD=5.8), a mean anticipatory pleasure capacity rating of 
43.6 (SD=7.9) and a mean defeatist performance belief score of 44.3 (SD=15.8).  
 
Overall, our study sample exhibited moderate to adequate levels of functioning, equivalent to a 
score between 20 and 24, with a mean global functioning score of 20.67 (SD=5.29). Total scores 
on the RFS ranged from a minimum score of 8 to a maximum score of 28. The distribution of 
total RFS scores within the sample (n=105) is shown in Figure 4.1.   Functional subdomain 
distributions showed that participants had the lowest levels of functioning in the subdomain of 
working productivity, with participants scoring a mean of 4.6 (SD=1.8) in comparison to the 
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other functional domains of independent living (mean=5.6, SD=1.5), immediate social networks 
(mean=5.4, SD=1.4), and extended social networks (mean=4.9, SD=1.5). However, given the 
range of possible scores, our study sample exhibited a moderate level of functioning, equivalent 
to an individual score of 5, in all four subdomains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Total RFS Scores for sample (n=105) 
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Table 4.1: Descriptive Statistics of Study Sample (n=105) 
Note: n= count; %=percentage; SD=standard deviation; Psychotic Disorder= psychosis not otherwise specified (n=3), brief psychotic disorder 
(n=2), psychosis due to medical condition (n=1), and substance induced psychosis (n=1)
Characteristic n (%) 
Gender  
Male 76 (72.38%) 
Female 29 (27.62%) 
Ethnicity  
European American 89 (84.76%) 
African American 4 (3.81%) 
Native American 3 (2.86%) 
Asian/Pacific Islander 5 (4.76%) 
Other 4 (3.81%) 
Marital Status  
Single 78 (74.29%) 
Married/Common Law 20 (19.05%) 
Separated/Divorced/Widowed 7 (6.67%) 
Living Arrangement  
Lives Alone 34 (32.38%) 
Lives with Other(s) 71 (67.62%) 
Employment Status  
Employed 51 (48.57%) 
Unemployed 48 (45.71%) 
Student  3 (2.86%) 
Annual Income  
Less than $10,000 to $29,999 90 (87.38%) 
$30,000 to $49,999 13 (12.62%) 
Primary Diagnosis  
Schizophrenia  94 (89.52%) 
Affective Disorder(s) 4 (3.81%) 
Psychotic Disorder(s) 7 (6.67%) 
Drug Use  
None 68 (64.76%) 
Below Cut off (<6) 22 (20.95%) 
Above Cut off (>=6) 15 (14.29%) 
Alcohol Use  
None 40 (38.10%) 
Below Cut off (<6) 50 (47.62%) 
Above Cut off (>=6) 15 (14.29%) 
Characteristic Mean (SD) Median Range 
Age 34.16 (9.86) 33 19 to 60 
Education (in years) 13.03 (2.04 13 8 to17 
Negative Symptoms 14.39 (15.79) 8 0 to 62 
Positive Symptoms 11.81 (13.98) 6 0 to72 
Self-Efficacy 30.95 (5.81) 31 10 to 40 
Anticipatory Pleasure Capacity 43.55 (7.92) 44 20 to 60 
Defeatist Performance Beliefs  44.31 (15.78) 44 15 to 87 
Functioning    
Global Functioning Score  20.67 (5.29) 22 8 to 28 
Working Productivity 4.63 (1.78) 5 1 to 7 
Independent Living and Self-Care 5.63 (1.51) 6 2 to7 
Immediate Social Networks 5.44 (1.37) 6 2 to 7 
Extended Social Networks 4.97 (1.53) 6 2 to 7 
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4.2 Correlation Analyses 
In order to assess the degree of overlap between measures of negative symptoms and 
functioning, we first conducted a series of bivariate correlation analyses. Findings from our 
correlation analyses can be found in Table 4.2.1, depicting Pearson correlation coefficients 
between total and subdomain scores of the SANS and RFS.  
 
The Pearson correlation coefficient (r) values revealed significant negative associations between 
overall functioning and total negative symptoms (r=-0.74, p<0.0001), as well as with the 
negative symptom subdomains of Avolition (r=-0.75, p<0.0001) and Anhedonia (r=-0.70, 
p<0.0001).  Negative Affect (r=-0.54, p<0.0001), Alogia (r=-0.45, p<0.0001), and Attention (r=-
0.57, p<0.0001) were found to have moderate associations with overall functioning. In 
comparing the negative symptom domain of avolition to the functional subdomains, findings 
demonstrate that avolition, as measured by the SANS, was more strongly correlated with 
working productivity (r=-0.70, p<0.0001) than the other functional subdomains. As well, the 
domains of the SANS demonstrated high correlation between negative symptoms subdomains. 
Avolition was shown to have a significant positive association with Anhedonia (r=0.755, 
p<0.0001). Anhedonia however also exhibited moderate positive associations with Alogia 
(r=0.556, p<0.0001) and Attention (r=0.625, p<0.0001) and Negative Affect also had moderate 
positive relationships with Alogia (r=0.503, p<0.0001) and Attention (r=0.566, p<0.0001). 
 
Findings from our correlation analyses assessing the relationship between the drivers of 
motivation, avolition and functional outcomes can be found in Table 4.2.2. Pearson correlation 
coefficients depicted significant negative associations between avolition and self-efficacy (r=-
0.33, p<0.0001) and anticipatory pleasure capacity (r=-0.13, p<0.0001), respectively although 
associations were small. As well, a small yet significant, positive association was found between 
avolition and defeatist performance beliefs (r=0.20, p<0.0001).  
 
Correlations between the drivers of motivation and functional outcomes demonstrate small yet 
significant relationships between each driver of motivation and overall functioning. However, 
differences between the drivers of motivation can be observed through their relationship to 
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specific functional subdomains. Self-efficacy was found to have a significant, small association 
with both working productivity (r=0.23, p<0.05), and extended social networks (r=0.29, p<0.01). 
Anticipatory pleasure capacity was positively associated with both immediate and extended 
social networks (r=0.29, p<0.01; r=0.28, p<0.01), respectively, whereas defeatist performance 
beliefs were negatively associated with independent living and self-care (r=-0.24, p<0.05), and 
immediate social networks (r=-0.26, p<0.01). 
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Table 4.2.1: Correlations between Negative Symptoms and Functioning Variables 
 
  Negative Symptoms Functional Outcomes 
  SANS 
Total 
Avolition Anhedonia Blunted 
Affect 
Alogia Attention RFS 
Total 
WP ILSC ISN ESN 
Negative 
Symptoms 
SANS 
Total 
-           
Avolition 0.79* -          
Anhedonia 0.84* 0.76* -         
Blunted 
Affect 
0.66* 0.38* 0.41* -        
Alogia 0.83* 0.53* 0.56* 0.50* -       
Attention 0.92* 0.59* 0.63* 0.57* 0.81* -      
Functional 
Outcomes  
RFS Total -0.74* -0.75* -0.70* -0.54* -0.45* -0.57* -     
WP -0.61* -0.70* -0.56* -0.49* -0.36* -0.45* 0.87* -    
ILSC -0.60* -0.54* -0.48* -0.50* -0.32* -0.56* 0.79* 0.57* -   
ISN -0.68* -0.65* -0.72* -0.45* -0.45* -0.51* 0.89* 0.66* 0.65* -  
ESN -0.64* -0.68* -0.65* -0.43* -0.42* -0.46* 0.87* 0.69* 0.50* 0.77* - 
Note: SANS Total= Total score on the Scale for the Assessment of Negative Symptoms; RFS Total=Total score on the Role Functioning Scale; WP= Working 
Productivity; ILSC=Independent Living and Self-Care; ISN= Immediate Social Networks; ESN=Extended Social Networks; n=105, *=significant at p<0.0001 
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Table 4.2.2 Correlations between Drivers of Motivation, Avolition and Functional Outcomes  
 
  Motivational Drivers  Functional Outcomes 
  GSE TEPS-A DPB Avolition RFS 
Total 
WP ILSC ISN ESN 
Motivational 
Drivers 
GSE -         
TEPS-A 0.38** -        
DPB -0.43** -0.34** -       
 Avolition -0.33** -0.13** 0.20** -      
Functional 
Outcomes  
RFS 
Total 
0.24* 0.20* -0.21* - -     
WP 0.23* 0.10 -0.13 - 0.87** -    
ILSC 0.12 0.04 -0.24* - 0.79** 0.57** -   
ISN 0.18 0.29** -0.26** - 0.89** 0.65** 0.65** -  
ESN 0.29** 0.28** -0.13 - 0.87** 0.70** 0.50** 0.77** - 
Note: GSE= Generalized Self Efficacy; TEPS-A=Anticipatory Pleasure Capacity; DPB=Defeatist Performance Beliefs; RFS Total=Total score on the Role 
Functioning Scale; WP= Working Productivity; ILSC=Independent Living and Self-Care; ISN= Immediate Social Networks; ESN=Extended Social Networks; 
n=105, *=significant at p<0.05, **=significant at p<0.01 
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4.3 Objective 1 
Table 4.3 presents the results of our unadjusted and adjusted linear regression models, with the 
exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist performance 
beliefs, and the outcome being global functioning. 
 
4.3.1 Exposure Variables 
Self-Efficacy 
In our unadjusted model, results suggest a positive relationship between self-efficacy and overall 
functioning (β=0.22, 95% CI: 0.05 to 0.39) with global functioning scores increasing as self-
efficacy scores increased. However, when included within the fully adjusted model, this 
relationship was no longer statistically significant (β=0.14, 95% CI: -0.09 to 0.36). 
 
Anticipatory Pleasure Capacity 
Findings from our unadjusted models showed a positive relationship between anticipatory 
pleasure capacity and overall functioning (β=0.13, 95% CI: 0.00 to 0.26) with global functioning 
score increasing as one’s capacity to experience anticipatory pleasure increased. However, this 
relationship was no longer statistically significant in the fully adjusted model (β=0.00, 95% CI: -
0.15 to 0.15). 
 
Defeatist Performance Beliefs 
Results from our unadjusted model showed a negative relationship between defeatist 
performance beliefs and overall function (β=-0.07, 95% CI: -0.13 to -0.00) with global 
functioning scores decreasing as defeatist performance beliefs increased. However this 
relationship was no longer statistically significant when assessed within our fully adjusted model 
(β=0.01, 95% CI: -0.07 to 0.09). 
 
4.3.2 Covariate Variables  
When assessing our unadjusted model, we see that the variables education, perceived social 
support, positive symptoms, depression and drug and alcohol use were associated with overall 
functioning. However only education and alcohol use remained statistically significant across our 
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models. Specifically, in our unadjusted model, we found level of functioning increased with 
increasing years of education (β=0.88, 95% CI: 0.35 to 1.40). In comparison to individuals with 
no reported alcohol use, individuals who reported some alcohol use, however not enough to be 
considered alcohol abuse, were associated with increased overall functioning (β=3.42, 95% CI: 
1.28 to 5.56).  However, both of these relationships were attenuated within our fully adjusted 
model (β=0.58, 95% CI: 0.07 to 1.09; β=2.35, 95% CI: 0.09 to 4.62). 
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Table 4.3: Unadjusted and Adjusted Linear Regression Models with the Outcome of Overall Functional Capacity (n=105) 
Variables Categorical 
Values 
Unadjusted Exposure β  
(95% CI) 
Unadjusted Covariate β  
(95% CI) 
Fully Adjusted  β 
 (95% CI) 
Exposure Variables     
Self-Efficacy N/A 0.22 (0.05 to 0.39) *  0.14 (-0.09 to 0.36) 
Anticipatory Pleasure N/A 0.13 (0.00 to 0.26) *  0.00 (-0.15 to 0.15) 
Defeatist Performance Beliefs N/A -0.07 (-0.13 to -0.00) *  0.01 (-0.07 to 0.09) 
Covariates     
Age N/A  0.06 (-0.05 to 0.16)  0.04 (-0.09 to 0.18) 
Gender  Male  -2.13 (-4.39 to 0.13) -0.94 (-3.43 to 1.55) 
Female  Ref. Ref. 
Education (years) N/A  0.88 (0.35 to 1.40) * 0.58 (0.07 to 1.09) * 
Length of Treatment (years) N/A  0.08 (-0.10 to 0.26) -0.06 (-0.31 to 0.19) 
Perceived Social Support N/A  0.22 (0.09 to 0.35) * 0.14 (-0.05 to 0.34) 
Positive Symptoms N/A  -0.10 (-0.17 to -0.03) * -0.05 (-0.12 to 0.02) 
Depressive Symptoms N/A  -1.56 (-2.96 to -0.16) * 0.46 (-1.93 to 2.84) 
Anxiety Symptoms N/A  -0.92 (-2.07 to 0.23) -0.26 (-2.11 to 1.58) 
Drug Use None  Ref. Ref. 
Below Cut-Off  2.93 (0.45 to 5.41) * 0.98 (-1.77 to 3.72) 
Above Cut-Off  -2.32 (-5.19 to 0.56) -1.97 (-5.28 to 1.33) 
Alcohol Use None  Ref. Ref. 
Below Cut-Off  3.42 (1.28 to 5.56) * 2.35 (0.09 to 4.62) * 
Above Cut-Off  2.68 (-0.37 to 5.74) 2.32 (-1.04 to 5.68) 
Medication Adherence 0-50%  Ref/ Ref. 
50-100%  -0.89 (-4.01 to 2.23) -1.68 (-4.78 to 1.41) 
Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables 
and covariates; R2=0.33; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable 
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4.4 Objective 2 
4.4.1 Working Productivity 
Table 4.4 contains the results of our unadjusted and fully adjusted linear regression models, with 
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist 
performance beliefs, and the outcome being the functioning subdomain of working productivity. 
 
4.4.1.1 Exposure Variables  
Self-Efficacy 
In our unadjusted model, results suggest a positive relationship between self-efficacy and 
working productivity (β=0.07, 95% CI: 0.01 to 0.13) with scores on the functional subdomain of 
working productivity increasing as self-efficacy scores increased. This association remains 
largely unchanged in the fully adjusted model; however, the 95% confidence interval now 
includes the null value and is no longer statistically significant (β=0.07, 95% CI: -0.00 to 0.15). 
 
Anticipatory Pleasure Capacity 
There was no evidence of a relationship between anticipatory pleasure capacity and the 
functional subdomain of working productivity (Table 4.4).  
 
Defeatist Performance Beliefs 
There was no evidence of a relationship between defeatist performance beliefs and the functional 
subdomain of working productivity (Table 4.4).  
 
4.4.1.2 Covariate Variables  
When assessing our unadjusted model, we see that the variables education, perceived social 
support, positive symptoms, and alcohol use were associated with one’s level of working 
productivity. However, these associations were no longer statistically significant within our fully 
adjusted model.  
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Table 4.4: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Working 
Productivity (n=105). 
 
Variables Categorical Values Unadjusted Exposure β  
(95% CI) 
Unadjusted Covariate β  
(95% CI) 
Fully Adjusted β 
 (95% CI) 
Exposure Variables     
Self-Efficacy N/A 0.07 (0.01 to 0.13) *  0.07 (-0.00 to 0.15) 
Anticipatory Pleasure N/A 0.02 (-0.03 to 0.06)  -0.02 (-0.08 to 0.03) 
Defeatist Performance Beliefs N/A -0.01 (-0.03 to 0.01)  0.01 (-0.01 to 0.04) 
Covariates     
Age N/A  0.00 (-0.03 to 0.04) -0.02 (-0.07 to 0.03) 
Gender  Male  -0.56 (-1.33 to 0.20) -0.51 (-1.39 to 0.36) 
Female  Ref. Ref. 
Education (years) N/A  0.25 (0.07 to 0.42) * 0.17 (-0.01 to 0.35) 
Length of Treatment (years) N/A  0.02 (-0.04 to 0.08) 0.01 (-0.08 to 0.10) 
Perceived Social Support N/A  0.06 (0.02 to 0.11) * 0.04 (-0.03 to 0.11) 
Positive Symptoms N/A  -0.04 (-0.06 to -0.01) * -0.02 (-0.05 to 0.00) 
Depressive Symptoms N/A  -0.42 (-0.90 to 0.05) 0.25 (-0.59 to 1.10) 
Anxiety Symptoms N/A  -0.29 (-0.68 to 0.10) -0.22 (-0.87 to 0.43) 
Drug Use None  Ref. Ref. 
Below Cut-Off  0.69 (-0.16 to 1.53) 0.08 (-0.88 to 1.04) 
Above Cut-Off  -0.72 (-1.71 to 0.27) -0.58 (-1.73 to 0.58) 
Alcohol Use None  Ref. Ref. 
Below Cut-Off  0.82 (0.08 to 1.56) * 0.60 (-0.20 to 1.39) 
Above Cut-Off  0.66 (-0.39 to 1.71) 0.63 (-0.54 to 1.81) 
Medication Adherence 0-50%  Ref. Ref. 
50-100%  -0.33 (-1.38 to 0.72) -0.65 (-1.73 to 0.43) 
Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables 
and covariates; R2=0.27; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable 
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4.4.2  Independent Living and Self-Care 
Table 4.5 presents the results of our unadjusted and fully adjusted linear regression models, with 
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist 
performance beliefs, and the outcome being the functioning subdomain of independent living 
and self-care. 
 
4.4.2.1 Exposure Variables  
Self-Efficacy 
There was no evidence of a relationship between self-efficacy and the functional subdomain of 
independent living and self-care (Table 4.5).  
 
Anticipatory Pleasure Capacity 
There was no evidence of a relationship between anticipatory pleasure capacity and the 
functional subdomain of independent living and self-care (Table 4.5).  
 
Defeatist Performance Beliefs 
In our unadjusted model, there was a small negative relationship between defeatist performance 
beliefs and independent living and self-care (β=-0.02, 95% CI: -0.04 to -0.00) with scores on the 
functional subdomain of independent living and self-care decreasing as defeatist performance 
belief scores increased. However, when included within the fully adjusted model, this 
relationship was no longer statistically significant (β=-0.01, 95% CI: -0.03 to 0.02). 
 
4.4.2.2 Covariate Variables  
When assessing our unadjusted model, we see that the variables age, positive symptom severity, 
depressive symptoms and drug and alcohol use were associated with independent living and self-
care. However only drug and alcohol use remained statistically significant across our models.  
Drug use above the cut-off score, meaning frequent drug use categorized as drug abuse, was 
found to have a negative association with independent living and self-care (β=-1.05, 95% CI: -
1.86 to -0.23) when compared to those that reported no drug use. Alcohol use below the cut-off 
score, meaning some alcohol use however not enough to be considered alcohol abuse, was found 
to have a positive association with independent living and self-care (β=0.97, 95% CI: 0.35 to 
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1.58) when compared to those that reported no alcohol use. These two relationships were 
attenuated within our fully adjusted model (β=-0.98, 95% CI: -1.94 to -0.01; β=0.85, 95% CI: 
0.19 to 1.51) but remained statistically significant. 
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Table 4.5: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Independent 
Living and Self-Care (n=105). 
 
Variables Categorical Values Unadjusted Exposure β  
(95% CI) 
Unadjusted Covariate β  
(95% CI) 
Fully Adjusted β 
 (95% CI) 
Exposure Variables     
Self-Efficacy N/A 0.03 (-0.02 to 0.08)  0.01 (-0.06 to 0.07) 
Anticipatory Pleasure N/A 0.01 (-0.03 to 0.04)  -0.02 (-0.06 to 0.03) 
Defeatist Performance Beliefs N/A -0.02 (-0.04 to -0.00) *  -0.01 (-0.03 to 0.02) 
Covariates     
Age N/A  0.04 (0.01 to 0.06) * 0.03 (-0.01 to 0.07) 
Gender  Male  -0.51 (-1.16 to 0.14) -0.01 (-0.74 to 0.72) 
Female  Ref. Ref. 
Education (years) N/A  0.18 (0.03 to 0.33) * 0.10 (-0.05 to 0.25) 
Length of Treatment (years) N/A  0.04 (-0.01 to 0.09) -0.04 (-0.11 to 0.04) 
Perceived Social Support  N/A  0.03 (-0.01 to 0.07) 0.00 (-0.05 to 0.06) 
Positive Symptoms N/A  -0.03 (-0.05 to -0.01) * -0.01 (-0.03 to 0.01) 
Depressive Symptoms N/A  -0.40 (-0.80 to -0.00) * -0.07 (-0.78 to 0.64) 
Anxiety Symptoms N/A  -0.32 (-0.65 to 0.01) -0.11 (-0.65 to 0.43) 
Drug Use None  Ref. Ref. 
Below Cut-Off  0.63 (-0.07 to 1.33) 0.29 (-0.51 to 1.10) 
Above Cut-Off  -1.05 (-1.86 to -0.23) * -0.98 (-1.94 to -0.01) * 
Alcohol Use None  Ref. Ref. 
Below Cut-Off  0.97 (0.35 to 1.58) * 0.85 (0.19 to 1.51) * 
Above Cut-Off  0.35 (-0.52 to 1.23) 0.58 (-0.41 to 1.57) 
Medication Adherence 0-50%  Ref. Ref. 
50-100%  -0.07 (-0.96 to 0.82) -0.15 (-1.06 to 0.75) 
Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables 
and covariates; R2=0.28; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable 
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4.4.3 Immediate Social Networks 
Table 4.6 contains the results of our unadjusted and fully adjusted linear regression models, with 
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist 
performance beliefs, and the outcome being the functioning subdomain of immediate social 
networks. 
 
4.4.3.1 Exposure Variables  
Self-Efficacy 
There was no evidence of a relationship between self-efficacy and the functional subdomain of 
immediate social networks (Table 4.6).  
 
Anticipatory Pleasure Capacity 
Findings from our unadjusted models showed a positive relationship between anticipatory 
pleasure capacity and the functional subdomain of immediate social networks (β=0.05, 95% CI: 
0.02 to 0.08) with immediate social network scores increasing as one’s capacity to experience 
anticipatory pleasure increased. However, this relationship was no longer statistically significant 
when assessed within our fully adjusted model (β=0.02, 95% CI: -0.02 to 0.06). 
 
Defeatist Performance Beliefs 
In our unadjusted model, results suggest a small negative relationship between defeatist 
performance beliefs and immediate social networks (β=-0.02, 95% CI: -0.04 to -0.00) with 
scores on the functional subdomain of immediate social networks decreasing as defeatist 
performance belief scores increased. However, when included within the fully adjusted model, 
this relationship was no longer statistically significant (β=-0.01, 95% CI: -0.03 to 0.02). 
 
4.4.3.2 Covariate Variables  
When assessing our unadjusted model, we see that the variables education, perceived social 
support, positive symptom severity and alcohol use were associated with the functional domain 
of immediate social networks. However, only education, perceived social support and alcohol 
use remained statistically significant across models.  In both our unadjusted and fully adjusted 
linear regression models, education was found to be associated with the functional subdomain of 
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immediate social networks (β=0.23, 95% CI: 0.10 to 0.37; β=0.16, 95% CI: 0.03 to 0.30) with 
immediate social network scores increasing as years of education increased. As with education, 
in both our unadjusted and fully adjusted linear regression models, perceived social support was 
found to be associated with the functional subdomain of immediate social networks (β=0.07, 
95% CI: 0.03 to 0.10; β=0.06, 95% CI: 0.01 to 0.11) with immediate social network scores 
increasing as perceived social support increased. Alcohol use below the cut-off was found to 
have an association with immediate social networks (β=0.90, 95% CI: 0.34 to 1.46; β=0.60, 95% 
CI: 0.01 to 1.20) when compared to those that reported no alcohol use. Findings demonstrated 
that the relationships between this functional domain and education and alcohol usage were 
attenuated when covariate variables were included within the regression model.  
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Table 4.6: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Immediate 
Social Networks (n=105). 
 
Variables Categorical Values Unadjusted Exposure β  
(95% CI) 
Unadjusted Covariate β  
(95% CI) 
Fully Adjusted β 
 (95% CI) 
Exposure Variables     
Self-Efficacy N/A 0.04 (-0.00 to 0.09)  -0.00 (-0.06 to 0.05) 
Anticipatory Pleasure N/A 0.05 (0.02 to 0.08) *  0.02 (-0.02 to 0.06) 
Defeatist Performance Beliefs N/A -0.02 (-0.04 to -0.00) *  -0.01 (-0.03 to 0.01) 
Covariates     
Age N/A  0.01 (-0.02 to 0.04) 0.00 (-0.03 to 0.04) 
Gender  Male  -0.40 (-0.99 to 0.20) -0.11 (-0.75 to 0.54) 
Female  Ref. Ref. 
Education (years) N/A  0.23 (0.10 to 0.37) * 0.16 (0.03 to 0.30) * 
Length of Treatment (years) N/A  0.03 (-0.02 to 0.07) 0.01 (-0.06 to 0.07) 
Perceived Social Support  N/A  0.07 (0.03 to 0.10) * 0.06 (0.01 to 0.11) * 
Positive Symptoms N/A  -0.02 (-0.04 to -0.00) * -0.01 (-0.03 to 0.01) 
Depressive Symptoms N/A  -0.34 (-0.71 to 0.02) 0.21 (-0.40 to 0.83) 
Anxiety Symptoms N/A  -0.18 (-0.48 to 0.13) 0.07 (-0.41 to 0.55) 
Drug Use None  Ref. Ref. 
Below Cut-Off  0.63 (-0.03 to 1.29) 0.09 (-0.63 to 0.80) 
Above Cut-Off  -0.44 (-1.20 to 0.33) -0.30 (-1.16 to 0.56) 
Alcohol Use None  Ref. Ref. 
Below Cut-Off  0.90 (0.34 to 1.46) * 0.60 (0.01 to 1.20) * 
Above Cut-Off  0.53 (-0.27 to 1.33) 0.32 (-0.55 to 1.20) 
Medication Adherence 0-50%  Ref. Ref. 
50-100%  -0.28 (-1.20 to 0.53) -0.46 (-1.27 to 0.35) 
Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables 
and covariates; R2=0.34; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable 
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4.4.4 Extended Social Networks 
Table 4.7 contains the results of our unadjusted and fully adjusted linear regression models, with 
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist 
performance beliefs, and the outcome being the functioning subdomain of extended social 
networks. 
 
4.4.4.1 Exposure Variables  
Self-Efficacy 
In our unadjusted model, results suggest a positive relationship between self-efficacy and the 
functional subdomain of extended social networks (β=0.07, 95% CI: 0.02 to 0.12) with extended 
social networks scores increasing as self-efficacy scores increased. However, when included 
within the fully adjusted model, this relationship was no longer statistically significant (β=0.06, 
95% CI: -0.01 to 0.12). 
 
Anticipatory Pleasure Capacity 
Findings from our unadjusted models showed a positive relationship between anticipatory 
pleasure capacity and the functional subdomain of extended social networks (β=0.05, 95% CI: 
0.02 to 0.09) with extended social network scores increasing as one’s capacity to experience 
anticipatory pleasure increased. However, this relationship was no longer statistically significant 
when assessed within our fully adjusted model (β=0.02, 95% CI: -0.02 to 0.06). 
 
Defeatist Performance Beliefs 
There was no evidence of a relationship between defeatist performance beliefs and the functional 
subdomain of extended social networks (Table 4.7).  
 
4.4.4.2 Covariate Variables  
When assessing our unadjusted model, we see that the variables gender, education, perceived 
social support, and drug and alcohol use were associated with the functional domain of extended 
social networks. However only education remained statistically significant across models. In 
both our unadjusted and fully adjusted linear regression models, education was found to be 
significantly associated with the functional subdomain of extended social networks (β=0.21, 95% 
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CI: 0.06 to 0.37; β=0.15, 95% CI: 0.01 to 0.30) with extended social network scores increasing 
as years of education increased. Findings demonstrated that this relationship was attenuated 
when covariate variables were included within the regression model. 
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Table 4.7: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Extended 
Social Networks (n=105). 
 
Variables Categorical Values Unadjusted Exposure β  
(95% CI) 
Unadjusted Covariate β  
(95% CI) 
Fully Adjusted β 
 (95% CI) 
Exposure Variables     
Self-Efficacy N/A 0.07 (0.02 to 0.12) *  0.06 (-0.01 to 0.12) 
Anticipatory Pleasure N/A 0.05 (0.02 to 0.09) *  0.02 (-0.02 to 0.06) 
Defeatist Performance Beliefs N/A -0.01 (-0.03 to 0.01)  0.01 (-0.01 to 0.04) 
Covariates     
Age N/A  0.01 (-0.02 to 0.04) 0.02 (-0.02 to 0.06) 
Gender  Male  -0.66 (-1.31 to -0.01) * -0.30 (-1.03 to 0.42) 
Female  Ref. Ref. 
Education (years) N/A  0.21 (0.06 to 0.37) * 0.15 (0.01 to 0.30) * 
Length of Treatment (years) N/A  -0.00 (-0.05 to 0.05) -0.04 (-0.12 to 0.03) 
Perceived Social Support  N/A  0.06 (0.02 to 0.10) * 0.04 (-0.02 to 0.10) 
Positive Symptoms N/A  -0.02 (-0.04 to 0.00) -0.01 (-0.03 to 0.01) 
Depressive Symptoms N/A  -0.39 (-0.80 to 0.01) 0.06 (-0.63 to 0.45) 
Anxiety Symptoms N/A  -0.13 (-0.47 to 0.20) -0.00 (-0.54 to 0.53) 
Drug Use None  Ref. Ref. 
Below Cut-Off  0.99 (0.27 to 1.71) * 0.52 (-0.28 to 1.32) 
Above Cut-Off  -0.11 (-0.95 to 0.73) -0.12 (-1.09 to 0.84) 
Alcohol Use None  Ref. Ref. 
Below Cut-Off  0.74 (0.11 to 1.36) * 0.30 (-0.36 to 0.97) 
Above Cut-Off  1.14 (0.25 to 2.03) * 0.79 (-0.20 to 1.77) 
Medication Adherence 0-50%  Ref. Ref. 
50-100%  -0.20 (-1.11 to 0.70) -0.42 (-1.33 to 0.48) 
Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables 
and covariates; R2=0.30; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable 
  
69 
 
4.5 Sensitivity Analyses 
4.5.1  Sensitivity Analyses Using Additional Variables 
4.5.1.1 Objective 1 
Results from our sensitivity analyses including an additional four variables, being age of onset, 
mode of onset, duration of untreated psychosis and premorbid adjustment, were consistent with 
our main analyses in that no significant relationship was observed between our exposure 
variables and overall functioning and effect estimates were comparable in magnitude.  
 
Among the additional variables assessed, premorbid adjustment and mode of onset were found to 
be associated with global functioning. Results from our unadjusted models showed a statistically 
significant relationship between global functioning and premorbid adjustment (β =-7.85, 95% CI: 
-15.18 to -0.51), however when included within the fully adjusted model this relationship was 
rendered no longer statistically significant. Mode of onset, although insignificant in our 
unadjusted model however was significant within our fully adjusted model (β =-4.03, 95% CI: -
7.86 to -0.19), demonstrating that when compared to those with an acute onset of psychosis, 
individuals with an insidious onset of psychosis had poorer functioning overall.  
 
4.5.1.2 Objective 2  
Similar findings were observed between our main analyses (n=105) and our sensitivity analyses 
(n=69) including four additional variables in regard to assessing each functional subdomain. 
Findings for each of our three exposure variables were consistent with our main analyses across 
functional subdomains. The magnitude of effect was smaller across all models with a narrower 
confidence interval.  
 
In regard to the functional subdomain of working productivity, our models did not show 
evidence of a significant association between age of onset, mode of onset, duration of untreated 
psychosis or premorbid adjustment with working productivity.  
 
When assessing the functional subdomain of independent living and self-care, although our 
unadjusted models showed age of onset and premorbid adjustment to be associated with 
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independent living and self-care (β =0.05, 95% CI: -0.01 to 0.10; β =-2.13, 95% CI: -4.15 to -
0.11), these associations did not hold in our full model.  
 
Unadjusted models assessing the functional domain of immediate social networks showed a 
significant association between the functional domain and premorbid adjustment (β =-2.37, 95% 
CI: -4.22 to -0.53) however, this relationship did not remain statistically significant within the 
full model. However, when controlling for the other identified factors, findings from our full 
model showed mode of onset, being the manner in which psychotic symptoms evolve during the 
first episode of psychosis, to be significantly correlated with the functional domain (β =-1.06, 
95% CI: -2.07 to -0.05). Similar to our findings for immediate social networks, a significant 
association between mode of onset and extended social networks was present within our full 
model (β =-1.38, 95% CI: -2.51 to -0.25). Although age of onset was shown to be significant in 
our unadjusted models, this relationship did not remain when controlling for other factors.  
 
4.5.2 Sensitivity Analyses Treating Outcome as Ordinal 
4.5.2.1 Objective 1 
Results from our sensitivity analyses treating the outcome of global functioning as measured on 
an ordinal scale found results consistent with our main analyses. Our exposure variables, being 
self-efficacy, anticipatory pleasure capacity and defeatist performance beliefs, remained non-
significant, although the magnitude of effect was smaller and had narrower associated 
confidence intervals in comparison with our main analyses.  
 
4.5.2.2 Objective 2 
In contrast to the main analyses, results from the sensitivity analyses treating the four functional 
subdomains, working productivity, independent living and self-care, immediate social networks 
and extended social networks, as measured on an ordinal scale found a small but statistically 
significant effect for self-efficacy with working productivity and extended social networks. 
Specifically, an increase in self-efficacy was associated with a decrease in the odds of being in a 
lower working productivity category, with an odds ratio of 0.91 (95% CI: 0.84 to 0.99), and a 
  
71 
 
decrease in the odds of being in a lower functioning category in terms of extended social 
networks with an odds ratio of 0.87 (95% CI: 0.80 to 0.95).  
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Chapter 5 
5 Discussion 
In this concluding chapter, an overview of key study findings, by objective, will be discussed and 
contextualized within the current evidence base. Section 5.1 will first discuss findings from our 
analyses examining the correlation between measures of negative symptoms and functioning, 
followed by a discussion of key findings from our linear regression models assessing the 
relationship between drivers of motivation and functioning, adjusting for potential covariates. 
Study strengths and limitations will then be discussed in Sections 5.2 and 5.3, respectively. 
Finally, translation of results for clinicians and researchers will be discussed in Section 5.4, 
followed by study conclusions in Section 5.5.  
 
5.1 Overview of Findings 
5.1.1 Correlational Analyses 
In recent years, a number of studies have examined the relationship between psychotic 
symptomatology and functional outcomes in individuals with psychotic disorders 
20,26,27,29,71,74,92,170. A relationship between negative symptoms and functional outcomes has been 
consistently found, with avolition being shown to be the strongest correlate than any other 
negative symptom subdomain. A 2012 study by Hunter and Barry investigated the relationship 
between negative symptoms and functioning using multiple measures of functioning. Their 
findings demonstrated strong, statistically significant correlations between the PANSS and five 
of six measures of functioning assessed 64. These scales included the Global Assessment of 
Functioning scale171, the Personal and Social Performance scale172, the Quality of Life Scale173, 
the Functional Remission of General Schizophrenia scale174 and the Psychosocial Remission in 
Schizophrenia scale175, as well as the Subjective Wellbeing under Neuroleptics scale176, which 
did not significantly correlate with the PANSS scores.  With findings such as these, conclusions 
have been made that negative symptoms are predictive of functional outcomes, specifically with 
motivational deficits being associated with poorer functioning. However, studies that found this 
strong correlation have used measures to assess negative symptoms that, although extensively 
used, do not discriminately measure the construct of negative symptoms separate from functional 
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outcomes, calling into question the validity of these measures given our current knowledge of 
negative symptoms. Specifically, when looking at the avolition sub-domain of the commonly 
used SANS, we see a high degree of overlap between the questions posed to assess one’s degree 
of avolition and measures used to assess functioning itself, as discussed in Chapter 2.  For 
example, the ability to care for one’s self in terms of grooming habits is considered a behavioral 
marker of functioning within the independent living and self-care domain of the RFS however it 
is also measured as part of the avolition sub-domain of the SANS as a behavioral marker of poor 
motivation (Appendix B and C). The questions posed to assess avolition fail to truly measure 
factors related to motivation and focus more on overt behavioral outcomes believed to be 
indicative of underlying motivation. Current measures of negative symptoms tap into behavioral 
achievement rather than the symptom itself and possibly fail to adequately address more 
experiential motivational deficits 9, which has been recognized as a limitation of current 
assessments of negative symptom domains 29,71. 
 
 We conducted a series of Pearson correlation analyses to see whether this relationship was 
present within our sample. Our analyses demonstrated moderate to strong, significant 
correlations between all domains of negative symptoms and functional outcomes, consistent with 
our hypothesis. Total scores on the SANS demonstrated a strong negative correlation to total 
scores on the RFS (r = -0.737, p<0.001) as well as with each subdomain (Table 4.2).The largest 
Pearson correlation coefficient was observed between the negative symptom domain of avolition 
and global functioning (r = -0.754, p<0.001), consistent with our hypothesis that these two 
domains would be highly correlated due to the high degree of overlap between measures. 
 
Although our correlations are consistent with ongoing discussions on measures of avolition and 
negative symptoms 23,25-27,29,71-74, we proposed that this association is present due to both 
domains measuring the same underlying constructs. We believe that our current method of 
measuring avolition may be erroneously connected to functioning due to the focus on assessing 
avolition using overt behavioral markers such as grooming habits and difficulty obtaining or 
maintaining employment - factors that are similarly found within scales assessing functioning. In 
other words, the strong relationship between negative symptoms, namely avolition, and 
functional outcomes that has been observed in the literature to date may be due to the two 
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domains being assessed using similar indicators, resulting in erroneous conclusions formed 
regarding the role of avolition as a predictor of functional outcomes. Through the literature we 
identified 3 psychological drivers of motivation that assess intrinsic motivational drivers rather 
than overt behavioral characteristics. Our correlation analyses demonstrated small yet significant 
relationships between all three of the drivers and avolition. As well, we observed differences 
between the motivational drivers and specific functional subdomains, in that certain 
psychological drivers of motivation were found to have significant associations with one or two 
functional subdomains rather than all four.  
 
5.1.2 Objective 1 
Although recent studies have recognized the issues associated with current measures of avolition 
in addition to other negative symptoms 29,71, no study to date has directly assessed the influence 
of motivational factors on functional outcomes, excluding negative symptoms scales. In order to 
better understand the relationship between avolition and functioning, we aimed to investigate 
whether drivers of motivation were associated with overall functional capacity in a sample of 
individuals with psychotic disorders. We had hypothesized that, given the existing literature 
showing that avolition has a dominant role in the development of poor functional outcomes, our 
identified drivers of motivation would each demonstrate a statistically significant association 
with overall functioning, namely that both self-efficacy and anticipatory pleasure capacity would 
have a significant, positive relationship with overall functioning, and defeatist performance 
beliefs would exhibit a significant, negative relationship with overall functioning.  
 
When assessing the relationship between the identified drivers of motivation and functioning, we 
found that each of the drivers assessed had a small but statistically significant relationship with 
overall functioning. However, when adjusting for our covariates, contrary to our hypothesis, we 
did not observe any statistically significant relationships between any of the motivational drivers 
and overall functioning in our fully adjusted model. Our findings therefore seem to be in 
disagreement with the current evidence base, in that our identified exposure variables, being 
considered primary indicators of motivation and therefore avolition, were not significantly 
associated with functioning in our multivariable analyses. 
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Comparison of our findings to past research assessing functional outcomes suggest that there is a 
possibility that the previously observed relationship between functioning and avolition was 
falsely identified due to the overlap between measures of negative symptoms and functioning. 
Given that our identified drivers of motivation can influence one’s degree of motivational 
deficits and therefore levels of avolition, it would stand to reason that if avolition and functional 
outcomes were associated with one another, then this relationship would still be observed via 
these motivational drivers. Buck and Lysaker 110 found that anticipatory pleasure deficits at 
baseline, as measured by the TEPS, was linked to poorer levels of interpersonal relations at 6-
month follow up among people with schizophrenia or schizoaffective disorder (n=51). As well, 
Ventura and Colleagues 28 conducted a study assessing the relationship between negative 
symptoms, neurocognition, and daily functioning along with what they termed “attitudinal 
beliefs” which included self-efficacy and defeatist performance beliefs. They also found strong 
correlations between self-efficacy and defeatist performance beliefs and global functioning. 
However, these analyses were univariate and failed to assess motivational drivers while 
controlling for confounding factors, which may explain the discrepancies between with our 
findings.  Other studies using these drivers of motivation have conducted mediation analyses 
using negative symptoms as mediators in the relationship between motivational drivers and 
functioning. Ventura and colleagues 28conducted one such analysis, where self-efficacy and 
defeatist performance beliefs were assessed for their indirect effect on functioning via negative 
symptoms. They found evidence consistent with a model where self-efficacy and defeatist 
performance beliefs, referred to as ‘dysfunctional attitudes’, had a partial influence on negative 
symptoms which in turn significantly influenced daily functioning levels. However, as with the 
previously stated analyses, no confounding factors were assessed which would likely affect study 
results, as observed in our analyses where the inclusion of covariates rendered the relationship 
between drivers of motivation and functioning non-significant. As well, given that these analyses 
included measures of negative symptoms, which we have shown overlap significantly with 
functional outcomes, it is possible that these previous findings were inflated.  
 
Although we found no significant relationship between overall functioning and any driver of 
motivation, results demonstrated that when adjusting for our covariate variables, total years of 
education and alcohol use exhibited a significant relationship with overall functioning. The 
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finding of education being significantly associated with overall functioning is consistent with 
findings reported by Santesteban-Echarri and colleagues,20 who conducted a meta-analysis 
assessing predictors of functional recovery in individuals with a first-episode of psychosis, with 
education being a significant correlate of functioning in 15 of 22 studies examining this variable 
(r=0.16, 95% CI: 0.11 to 0.20, p<0.00).  Taken together, these findings suggest that one’s level 
of education is related to overall functioning and that this association reflects a positive 
relationship between the two variables.  
 
Interestingly, alcohol usage below what is considered alcohol abuse, in comparison to 
individuals that reported no alcohol use, was found to have a significant, positive relationship 
with overall functioning, with individuals reporting some alcohol usage experiencing better 
overall functioning then those who reported no alcohol use. Although our measure of alcohol use 
was self-reported, similar findings have been reported with substance use177. Similar to our 
findings, Swartz and colleagues 177found that compared to individuals who were abstinent, those 
who used substances (alcohol or illicit drugs) without serious impairment or without diagnosis of 
a substance use disorder had higher overall psychosocial functioning and equivalent functioning. 
One potential explanation for these counterintuitive findings is that some degree of initiative, 
social contact, and organizational skills are required for engaging drug-involved peer and 
obtaining illicit substances 177.  
 
5.1.3 Objective 2 
To our knowledge, no study to date has examined the relationship between motivational drivers 
and specific subdomains of functioning. We hypothesized that each driver of motivation would 
have a different relationship with functioning; however, our results showed no statistically 
significant relationships between any of our drivers of motivation across all functioning 
subdomains when adjusting for possible covariate factors. Interestingly, we did find differences 
in our unadjusted models.  Self-efficacy, when not controlling for other variables, was found to 
be significantly correlated with both of the functional subdomains of working productivity and 
extended social networks. In our sensitivity analyses, these relationships remained significant 
within our fully adjusted model however effect sizes were small. Defeatist performance beliefs 
were the only motivational driver that was found to be correlated with the functional domain of 
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independent living and self-care. Defeatist performance beliefs were also found to have a 
significant association with extended social network functioning. Anticipatory pleasure capacity 
was found to be significantly associated with both immediate and extended social network 
subdomains. Therefore, although our fully adjusted models did not find significant associated 
between these variables and functioning, we did observe differences between drivers of 
motivation and functional subdomains.  
 
A number of covariates were found to be associated with the functional subdomains. Both 
alcohol use and drug use were found to be significantly associated with the functional subdomain 
of independent living and self-care. Education, social support, and alcohol use were found to 
have significant associations with the functional subdomain of immediate social networks. 
However, when assessing extended social networks, only education was found to be significantly 
correlated with functioning. Overall, education was shown to have the strongest relationship with 
functioning; being significantly correlated with overall functioning as well as 3 out of 4 
subdomains of functional outcomes. 
 
Our main analyses identified small yet significant relationships between all of our drivers of 
motivation and overall functioning within our unadjusted models, however we did not find a 
statistically significant relationship between the identified drivers of motivation and functioning 
after adjusting for covariates. Similar findings were shown in our models of each functional 
subdomains, with some drivers of motivation being shown to have a small but significant 
relationship to that functional domain. Our findings, although the first to assess these factors in 
conjunction with possible covariate factors and without the influence of negative symptoms, 
goes against previous studies of functional outcomes within a psychosis population. The current 
evidence base suggests that negative symptoms play an important role in the development of 
poor functional outcomes. However, our exposure variables, recognized to be factors that 
influence or “drive” motivation and therefore theoretically should be a direct influence on 
avolition, failed to support this theory. Self-efficacy, anticipatory pleasure capacity, and defeatist 
performance beliefs, although each identified as motivational targets, did not support the theory 
that avolition leads to poor functional outcomes. Therefore, our findings seem to propose that the 
previously observed relationship between negative symptoms, mainly avolition, and functional 
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outcomes may be inflated due to the overlapping measures used to measure these constructs and 
the lack of control for additional factors.  
 
5.2 Study Strengths 
This study had a number of strengths. Firstly, to our knowledge this was the first study to assess 
the relationship between functioning and avolition using measures that directly assess factors 
known to drive motivation. This effectively allowed for us to observe the relationship between 
motivation and functioning without overlapping measures which we believe has previously 
resulted in an inflated association between negative symptoms and functioning. Our study was 
unique in the consideration of multiple driving factors of motivation rather than a single factor. 
This allowed us to first assess whether there was in fact a relationship between motivation and 
functioning, and to ascertain whether certain factors exerted a stronger influence than others. 
 
 In contrast to previous studies assessing functional outcomes, we also included a number of 
potential covariate factors, including sociodemographic and clinical factors. Although a number 
of studies have been conducted assessing the relationship between negative symptoms and 
functioning and have found a significant relationship between the two, the majority of these 
studies did not include a wide range of potential covariates variables, and instead included other 
symptom domains such as positive symptoms and affective symptoms 26,28,29,71,110,170. Given that 
our literature search identified a number of factors that influence functioning, it is important to 
account for these factors in order to truly assess the relationship between motivation and 
functioning. Accounting for covariate variables is an important strength to this study as the 
factors found to be associated with functional outcomes across our models were variables 
identified as covariates and not our exposure variables. This illustrates that the strongest 
relationships with functioning were not found with motivational factors but rather variables such 
as education, length of treatment, alcohol use and drug use. As well, these variables were all 
analyzed using a series of simple and multivariable linear regression analyses, allowing for us to 
assess and estimate the independent effect of our exposure variables (self-efficacy, anticipatory 
pleasure capacity and defeatist performance beliefs), controlling for each other and for our 
identified potential covariates. Furthermore, the selection of covariates included within our 
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analyses were guided by our research using previous studies that make up the current evidence 
base.  
 
Lastly, we also re-assessed our findings for robustness by means of two sensitivity analyses. 
Given that our outcome of functioning is assessed on a Likert scale, we additionally ran our 
analyses using an ordinal logistic regression model to assess whether treating our outcome as 
continuous had affected our results. As well, we used a subset of our total sample to re-assess our 
exposure variables controlling for four additional variables that we had identified as possible 
covariates. Both sensitivity analyses were consistent with our main analyses, demonstrating the 
robustness of findings for this study.  
 
5.3 Study Limitations 
Although our study had a number of strengths, there were also some limitations that should be 
considered. This study design was cross-sectional, with data collection for each participant 
occurring at one time point. Findings from cross-sectional research is limited when discussing 
directionality of hypotheses. While the presence of associations, and whether they are positive or 
negative in nature, can be discussed, the directionality of these associations cannot be determined 
and any consideration of variables as cause and effect are solely theoretical in nature. 
Specifically, we cannot determine whether these motivational drivers impact functioning or 
whether poor functioning impacts motivation. Although we were able to show associations, or 
lack of, between our exposure variables and outcomes, cross-sectional research is also limited in 
regard to the statements and conclusions made when discussing causality. Longitudinal models 
would be better able to assess causality, namely, whether drivers of motivation have a causal role 
in functional outcomes. In previous studies, self-efficacy and defeatist performance beliefs have 
been identified as being fluid, with the possibility of change occurring over time. Given this 
understanding that motivational drivers are not stagnant and therefore motivational level can 
change, our cross-sectional study only pinpoints motivation at one time point. A longitudinal 
study assessing motivational drivers and functioning over time would allow one to form more 
concrete conclusions on the relationship between motivation and functioning in psychosis 
populations. We also acknowledge that the drivers of motivation were all assessed using self-
report measures and therefore may be influenced by response biases and/or factors affecting their 
  
80 
 
current mindset at the time of assessment such as a recent psychotic episode or increases in 
depressive symptoms. 
 
Furthermore, within our analyses we controlled for a number of covariates, with a few factors 
being found to have a significant association with functional outcomes. Although we controlled 
for these factors, based on our literature review which demonstrated their association with 
functional outcomes, as with our drivers of motivation we cannot determine the directionality of 
these variables in regard to both motivation and functioning. We chose to examine the direct 
effect of motivational drivers on functional outcomes, given the current discussion on avolition 
being the strongest influence on functioning. However, education was found to be significantly 
associated with overall functioning within our sample, and when included within our fully 
adjusted model this covariate remained significant while our motivational drivers did not. One 
could argue that motivational drivers may impact educational achievement, and consequently 
influence functional outcomes; thereby acting as a mediator in this relationship, or, that 
educational achievements may impact motivational drive, in turn affecting functioning. 
Therefore, there is a possibility that some of our covariates, such as education, depression or 
social support, may have a more integrated role within the causal pathway between motivational 
drivers and functioning, and that their inclusion within our fully-adjusted model resulted in over-
adjustment. However as indicated in Tables 4.3 to 4.7, our model diagnostics demonstrated that 
the R2 values calculated for each regression model ranged between 0.27 and 0.34 depending on 
the model; demonstrating that approximately 27% to 34% of the total variance was accounted for 
by our motivational drivers and covariates. Given that only a small proportion of the variance in 
functional outcomes was accounted for by the motivational drivers and covariates, there may be 
other factors that were not included within our models that may play an important role in the 
development of poor functional outcomes.  Further research should consider these possibilities, 
namely through a longitudinal study design to aid the discussion on possible mediational roles 
within the causal pathway. 
 
It should also be noted that our study was conducted using a sample that had been previously 
receiving treatment. The duration of untreated psychosis within a subset of our sample had a 
median value of 23.1weeks (IQR= 52.4), meaning that from the first signs of psychosis over half 
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of participants did not start receiving treatment for close to 6 months. Duration of untreated 
psychosis has been shown to be associated with poorer symptomatology and social functioning 
16,20. Given that early psychosis treatment is associated with numerous benefits in terms of 
symptomatic recovery, reduced risk of relapse and a better ability to preserve and develop 
psychosocial skills, it is possible that our results may be indicative of a more chronic population 
and not be generalizable to individuals who are first starting treatment. 
 
Additionally, our study sample was recruited from an early psychosis intervention program that 
had their own inclusion criteria, and the majority of study participants were male and Caucasian. 
Therefore, our conclusions may be limited to these clinical and demographic populations. 
Specifically, our findings may not be generalizable to individuals receiving treatment in other 
settings, females, individuals with affective psychotic disorders, or other ethnic minority groups 
who may face additional socio-economic barriers in regard to functioning. Notably, our study 
population also exhibited moderately high functioning with median global functioning scores of 
22 out of a possible score of 28. It is therefore possible that our study findings would not be 
generalizable to a more functionally-heterogeneous population. Future studies should address 
these limitations in more diverse samples. 
 
Although our sample was relatively large given the population and previous studies in the same 
field, our sample only included 105 participants whose data were used for our main analyses. 
However, within this sample we had to exclude data on four variables we identified as possible 
covariates, including age of onset, duration of untreated psychosis, premorbid adjustment and 
mode of onset. These variables were excluded from our main analyses because they were not 
assessed for the subset of our sample that were enrolled in the negative symptom study and 
therefore were assumed to be Missing Not at Random. This prohibited us from imputing these 
variables, given that the mechanism of missing data required for multiple imputation is for data 
to be Missing at Random. Although we were able to include these four variables in our 
sensitivity analyses, our sample size was reduced to include only those participants who were 
enrolled in the 10-year outcome study, a total of 69 individuals. Furthermore, given that we had a 
small sample size and controlled for a number of covariates, there is a possibility that we over-
fitted our models resulting in misleading findings regarding the relationship between our 
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identified drivers of motivation and functioning. The use of a small sample size for our main 
analyses, and a loss of sample size for our sensitivity analysis, reduces our statistical power, 
therefore further research on the topic using a larger sample size is needed.  
 
5.4 Study Implications and Future Directions 
The current evidence base suggests that negative symptoms, more so than any other factor, are 
significantly associated with level of functioning, both in the early stages of illness and in more 
chronic populations. However, our study using more intrinsic measures of motivation rather than 
measures of avolition, failed to support these findings and lends credence to the growing opinion 
that the current measurement of avolition specifically, and negative symptoms more broadly, is 
lacking. This calls for a greater recognition that there are other factors that may play a role in the 
extent of poor functioning observed within populations with psychosis. A growing evidence base 
has suggested that neurocognition is strongly associated with functional outcomes 178-182. 
Furthermore, a relationship between motivational deficits, neurocognitive elements and 
functioning has been proposed, with motivational deficits and neurocognitive factors influencing 
functional outcomes 183,184. Within our study, we focused on negative symptoms primarily and 
excluded neurocognitive variables; however, given that our analyses did not find a relationship 
between motivational drivers and functioning, future research should build upon past studies 
assessing the relationship between neurocognitive variables and functioning.  
 
Our study was the first to assess a number of different motivational factors and their relationship 
with functional outcomes, however, there are other possible factors that may influence one’s 
motivation level. Alternative variables such as self-stigma and fear of negative evaluations from 
others could affect one’s perception of ability in regard to goal achievement. Therefore, future 
research should address other types of motivational influences to form a better understanding of 
the impact of motivation on functioning.  
 
As well, our analyses showed that education, social support, and alcohol use were associated 
with functioning, highlighting the important role of social determinants on health outcomes. This 
reflects the need to also address recovery through socioeconomic engagement and participation, 
as well as the future development and implementation of health and social policy initiatives to 
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address the socioeconomic and health inequalities observed within psychosis populations 185,186. 
Enhancement of social participation, through engagement with community activities and 
connecting individuals with peer groups to form social support networks and develop social 
skills, in combination with current pharmacological/psychological treatment methods may 
provide additional benefits in regard to recovery, both symptomatic and functional.  
 
Importantly, findings from this study demonstrate a need for updated measures of avolition and 
negative symptoms. With motivational drive being composed of multiple factors, both intrinsic 
and extrinsic, there is a need for measures to include a broader assessment of motivational 
influences. Furthermore, the development of these measures should be conducted in a manner 
that takes into account the individual experiences of motivation, and what drives motivation, 
from individuals with experiences of avolition.   
 
5.5 Conclusions 
To our knowledge, this study was the first to assess the relationship between multiple drivers of 
motivation and functioning among people with psychotic disorders, in addition to formally 
recognizing the overlap between measures of negative symptoms and functioning. Findings from 
our study suggest that the relationship between avolition and negative symptoms may be 
artificially inflated due to the way avolition is measured, given that our more intrinsic measures 
of motivation failed to find effects similar to past studies that employed the use of avolition 
measures that overlapped with functioning measures. Other social determinants, such as 
education, substance use, and social support, were shown to have a stronger relationship with 
functioning, more so than any other factor included within our models. Further research 
examining drivers of motivation within a large prospective dataset is necessary to solidify our 
understanding regarding the influence of motivational drivers on functional outcomes. 
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Appendix B. Scale for the Assessment of Negative Symptoms -Avolition/Apathy and 
Anhedonia/Asociality Subdomains 
Scale for the Assessment of Negative Symptoms (SANS)  Page 2 
 
 
 
11. Blocking 0 1 2 3 4 5 
The patient indicates, either spontaneously or with prompting, that 
his or her train of thought was interrupted. 
 
12. Increased Latency of Response 0 1 2 3 4 5 
The patient takes a long time to reply to questions; prompting 
indicates the patient is aware of the question. 
 
13. Global Rating of Affective Flattening 0 1 2 3 4 5 
This rating should focus on overall severity of symptoms,  
especially unresponsiveness, eye contact, facial expression and 
vocal inflections. 
 
AVOLITION - APATHY 
 
14. Grooming and Hygiene 0 1 2 3 4 5 
The patient’s clothes may be sloppy or soiled, and he or she may have 
greasy hair, body odour, etc. 
 
15. Impersistence at Work or School 0 1 2 3 4 5 
The patient has difficulty seeking or maintaining employment,  
Completing school work, keeping house, etc. If an inpatient, cannot 
persist at ward activities, such as OT, playing cards, etc. 
 
16. Physical Anergia 0 1 2 3 4 5 
The patient tends to be physically inert. He or she may sit for hours 
and not initiate spontaneous activity. 
 
17. Global Rating of Avolition - Apathy 0 1 2 3 4 5 
Strong weight may be given to one or two prominent symptoms 
if particularly striking. 
 
ANHEDONIA – ASOCIALITY 
 
18. Recreational Interests and Activities 0 1 2 3 4 5 
The patient may have few or no interests. Both the quality and 
quantity of interests should be taken into account. 
 
19. Sexual Activity 0 1 2 3 4 5 
The patient may show decrease in sexual interest and activity,  
or enjoyment when active. 
 
20. Ability to Feel Intimacy and Closeness 0 1 2 3 4 5 
The patient may display an inability to form close or intimate 
relationships, especially with opposite sex and family. 
 
21. Relationships with Friends and Peers 0 1 2 3 4 5 
The patient may have few or no friends and may prefer to spend 
all of his her or her time isolated. 
 
22. Global Rating of Anhedonia - Asociality 0 1 2 3 4 5 
This rating should reflect overall severity, taking into account the 
patient’s age, family status, etc. 
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Appendix C. Role Functioning Scale
ROLE FUNCTIONING SCALE  (Goodman et al., 1993) 
 ID # _____________________  DATE: _________________________ 
 Working Productivity Independent Living, Self Care Immediate Social Network 
Relationships 
Extended Social Network 
Relationships 
Score 
Rate the client primarily in the most 
appropriate expected role (i.e., 
homemaker, student, wage earner) 
(Management of household, eating, 
sleeping, hygiene care) 
(Close friends, Spouse, Family) (Neighbourhood, community 
church, clubs, agencies, recreational 
activities) 
1 
Productivity severely limited; often 
unable to work or adapt to school or 
homemaking; virtually no skills or 
attempts to be productive 
Lacking self-care skills approaching life 
endangering threat; often involves 
multiple and lengthy hospital services; 
not physically able to participate in 
running a household 
Severely deviant behaviours within 
immediate social networks (i.e., often 
with imminent physical aggression  or 
abuse to others, or severely withdrawn 
from close friends, spouse, family; often 
rejected by immediate social network) 
Severely deviant behaviours within 
extended social networks (i.e., overtly 
disruptive, often leading to rejection by 
extended social networks). 
2 
Occasional attempts at productivity 
unsuccessfully; productive only with 
constant supervision in sheltered work, 
home or special classes. 
Marked limitations in self-
care/independent living; often involving 
constant supervision in or out of 
protective environment (e.g., frequent 
utilization of crisis services). 
Marked limitations in immediate 
interpersonal relationships (e.g. 
excessive dependency or destructive 
communication or behaviours). 
Often totally isolated from extended 
social networks, refusing community 
involvement or belligerent to helpers, 
neighbours, etc. 
3 
Limited productivity; often with 
restricted skills/abilities for 
homemaking, school, independent 
employment (e.g., requires highly 
structured routine). 
 
Limited self-care/independent living 
skills; often relying on mental/physical 
health care; limited participation in 
running household. 
Limited interpersonally; often no 
significant participation/ 
communication with immediate social 
network. 
Limited range of successful and 
appropriate interactions in extended 
social networks (i.e., often restricts 
community involvement to minimal 
survival level interactions). 
4 
Marginal productivity (e.g., productive 
in sheltered work or minimally 
productive in independent work; 
fluctuates at home, in school; frequent 
job changes). 
Marginally self-sufficient; often uses 
REGULAR assistance to maintain self-
care/ independent functioning; 
minimally participates in running 
household. 
Marginal functioning with immediate 
social network (i.e., relationships are 
often minimal and fluctuate in quality). 
Marginally effective interactions; often 
in a structured environment; may 
receive multiple public system support 
in accord with multiple needs. 
5 
Moderately functional in independent 
employment, at home or in school. 
(Consider very spotty work history or 
fluctuations in home, in school with 
extended periods of success.) 
Moderately self-sufficient; i.e., living 
independently with ROUTINE 
assistance (e.g., home visits by nurses, 
other helping persons, in private or self-
help residences). 
Moderately affective continuing and 
close relationship with at least one other 
person. 
Moderately affective and independent 
in community interactions; may receive 
some public support in accord with 
need. 
6 
Adequate functioning in independent 
employment, home or school; often not 
applying all available skills/abilities. 
Adequate independent living & self-
care with MINIMAL support (e.g., some 
transportation, shopping assistance 
with neighbours, friends, other helping 
persons). 
Adequate personal relationship with 
one or more immediate members of 
social network (e.g., friend or family). 
Adequately interacts in neighbourhood 
or with at least one community or other 
organization or recreational activity. 
7 
Optimally performs homemaking, 
school tasks or employment-related 
functions with ease and efficiency. 
 
Optimal care of health/hygiene, 
independently manages to meet 
personal needs and household tasks. 
Positive relationships with spouse or 
family and friends; assertively 
contributes to these relationships. 
Positively interacts in community; 
church or clubs, recreational activities, 
hobbies or personal interests, often with 
other participants. 
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Appendix D. Additional Information Pertaining to the Psychosis and Early Intervention 
Programme (PEPP) Services 
 
After admission, an individualized treatment plan is developed in collaboration with the client, 
and whenever possible, their family 121. Treatment plans are based on an assertive case 
management model which involve both medication management, involving the initiation of 
antipsychotic medication combined with psychosocial management, such as family 
interventions, group interventions, and individualized therapies provided by a nurse or case 
manager 120,121. Case managers assess, treat, and work through the patient’s recovery from 
psychosis which is achieved through working closely with patients and their families with the 
aim to reintegrate the patient to his or her full potential over a two-year period120,121. Patients 
may stay in this core intensive treatment programme for a minimum of two years with patients 
not recovered sufficiently to assume independent functioning and/or not in remission being 
provided with extended case management for an additional one to three years 14,120. However, the 
majority of patients graduate from this programme. All patients will continue with medical 
management with their respective psychiatrists for up to a total of five years with most patients 
being seen every one to three months while stable120,121.  
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Appendix E. Anticipatory Pleasure Subdomain Questions of the TEPS 
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Appendix F. Additional Covariate Variables 
Age of Onset 
Age of onset refers to one’s chronological age at the time of the first onset of psychotic 
symptoms, with psychotic symptoms being identified by hallucinations, delusions or gross 
disorganization 187. A younger age of onset has been found to be associated with poorer 
premorbid functioning 188 however, findings are mixed regarding the effect a younger age of 
onset has on functional outcomes 131,132,137,189-191. Age of onset was calculated via the 
Topography of Psychotic Episode (TOPE) section of the Course of Onset and Relapse Schedule 
(CORS)192, a structured interview that assesses lifetime history of illness prior to the onset of the 
current psychotic episode, using date of birth and date of initial behavioral changes. The CORS 
consists of 5 sections: (1) Identifying Information, (2) Demographic Information, (3) Family 
Structure and Health, (4) Pathways to Care, and (5) Topography of Psychotic Episode. 
 
The CORS was completed at baseline for the 10-year outcome study via information obtained 
from family members and the referral source however, this measure was not used for the 
negative symptom study. Given that a significant portion of our data set does not have data on 
age of onset, we were unable to include the variable in our main multivariable regression 
analyses and therefore only used the CORS as a continuous measure of age of onset for our 
descriptive statistics and sensitivity analyses. 
 
Mode of Onset 
Mode of onset refers to how quickly psychotic symptoms evolve during the first episode of 
psychosis 193. Mode of onset was calculated using the CORS by subtracting the date of onset of 
psychosis from the date of initial behavioral changes. 
 
The CORS was completed at baseline for the 10-year outcome study via information obtained 
from family members and the referral source however, this measure was not used for the 
negative symptom study. Given that a significant portion of our data set does not have data on 
mode of onset, we were unable to include the variable in our multivariable regression analyses 
and therefore only used the CORS as a dichotomous measure of mode of onset for our 
descriptive statistics and sensitivity analyses, with participants being categorized as having either 
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an acute or insidious mode of onset. An acute mode of onset was defined as a period of less than 
or equal to one month, whereas an insidious mode of onset was defined as more than one month. 
In individuals with psychotic disorders, an insidious onset of psychosis is associated with a 
greater duration of untreated psychosis 194and poorer functional outcomes193. 
 
Duration of Untreated Psychosis 
Duration of untreated psychosis was defined as the length of time, in weeks, from the onset of 
psychotic symptoms (e.g. hallucinations) to the date of two months post initiation of 
antipsychotic therapy. Information regarding the date of onset of symptoms and date of treatment 
were obtained from the CORS at baseline for the 10-year outcome study. Duration of untreated 
psychosis has been found to be associated with greater symptom severity 195,196, an insidious 
mode of onset 194, and poorer functional outcomes 16,20,195,196. 
 
The CORS has demonstrated high inter-rater reliability (ICC=0.86 to 0.90) for its ability to 
calculate duration of untreated psychosis 197 and has been used in studies of participants with a 
first episode of psychosis 198-200. Duration of untreated psychosis was treated as a continuous 
variable. 
 
Given that a significant portion of our data set does not have data on duration of untreated 
psychosis, we were unable to include the variable in our multivariable regression analyses and 
therefore only used the CORS as a continuous measure of duration of untreated psychosis for our 
descriptive statistics and sensitivity analyses. 
 
Premorbid Adjustment 
Premorbid adjustment refers to one’s psychosocial functioning prior to the onset of psychotic 
symptoms and was assessed using the Premorbid Adjustment Scale (PAS) 201 at baseline for the 
10-year outcome study. The PAS is a series of rating scales that evaluate five domains of 
functioning: (1) Sociability and Withdrawal, (2) Peer Relationships, (3) Scholastic 
Performance, (4) Adaptation to School, and (5) Social-sexual Aspects of Life. All or some of 
these domains of functioning are then assessed over four separate life periods including 
childhood (up to age 11), early adolescence (12 to 15), late adolescence (17 to 18) and adulthood 
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(19 and above). Social-sexual aspects of life is not assessed during the childhood life period, 
along with scholastic performance and adaptation to school being not assessed during the 
adulthood life period. Along with the four separate life periods, there is a general section which 
assesses variables including education, employment, school, establishment of independence, 
highest level of functioning, social-personal adjustment, degree of interest in life and energy 
level. 
 
Given that onset of illness typically occurs within the late adolescence and adulthood periods, 
these sections were excluded from our analyses to reduce the effects of confounding 187. 
Therefore, the ratings from the childhood and early adolescence periods were the section used 
for our analyses to assess premorbid adjustment. Each item of this scale is rated using a Likert-
type scale with responses ranging from 0 to 6. To calculate total scores for each psychosocial 
domain, ratings were summed for all items and divided by the total possible score, which 
resulted in total scores ranging from 0 to 6, with higher scores being indicative of worse 
adjustment. For all ratings, the premorbid period was used as a reference frame 201. Information 
on psychosocial functioning during this period was obtained from patient reports and reports 
from family members. Poorer premorbid functioning is associated with greater negative 
symptom severity 137,189,196,202, amotivation 141and poorer functional outcomes 20,130,132,137,202,203. 
 
Brill and colleagues conducted a study to test the predictive and concurrent validity of the PAS 
within a sample of 91 males diagnosed with either schizophrenia or schizoaffective disorder204. 
Their findings demonstrate a high degree of correlation between the PAS late adolescence scores 
and Draft Board assessments at age 17 years in terms of estimating premorbid functioning in 
schizophrenic persons. The correlation of the PAS in terms of school achievements and school 
adjustment items with the Draft Board assessments for functioning in structured environments 
were r=0.71 and r=0.72, respectively, for concurrent ratings and r=0.4 and r=0.47, respectively 
for the ratings obtained at the age of 17 204. The PAS was also found to have good reliability with 
a weighted ICC for absolute agreement and consistency of 0.77 204. 
 
For our analyses, we used the total premorbid adjustment scale rating for the childhood and early 
adolescence period and treated the score as a continuous variable for our descriptive statistics 
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and sensitivity analyses. However, we were unable to include the variable in our main 
multivariable regression analyses due to its exclusion in the negative symptom study resulting in 
a high degree of missing data and overall lack of variability within our data set.
  
113 
 
 
Curriculum Vitae 
 
 
Name: Sahana Kukan 
 
Post-Secondary 
Education and Degrees:  
M.Sc. Epidemiology and Biostatistics  
Western University  
London, ON 
 
B.Sc. Honors Psychology 
University of Waterloo 
Waterloo, ON 
2012-2016 
 
Related Work  
Experience: 
Graduate Student Assistant 
Department of Epidemiology and Biostatistics 
Western University 
January 2018-May 2018 
 
Graduate Research Assistant  
Parkwood Institute- Mental Health        
Sept. 2016-Present 
 
Research Assistant  
Department of Psychology  
University of Waterloo 
Sept. 2014-April 2016 
 
Presentations: Poster, March 2017: “The Novel Use of Participatory Video as a 
Recovery Oriented Intervention in Early Psychosis: A Pilot Study” 
• London Health Research Day, LHSC, London, ON 
 
Presentation, May 2017: “The Novel Use of Participatory Video as a 
Recovery Oriented Intervention in Early Psychosis: A Pilot Study” 
• Early Psychosis Intervention Ontario Network (EPION), 
Toronto, ON 
        
Poster, May 2018: “Examining the Relationship 
between Internal Drivers of Motivation and Functional Outcomes in a 
Cross-Section of Individuals with Psychotic Disorders” 
• London Health Research Day, LHSC, London, ON 
 
Poster, June 2018: “Examining the Relationship 
between Internal Drivers of Motivation and Functional Outcomes in a 
Cross-Section of Individuals with Psychotic Disorders” 
• Joint Mental Health Research Day, LHSC, London ON 
 
